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Abstract: 
Cardiovascular disease affects nearly half (121.5 million) of the adult US 
population. In many of these patients, atherosclerotic lesions lead to coronary and 
peripheral artery disease, causing ischemia of the heart and limbs. Arteriogenesis, a 
natural compensatory mechanism, restores blood flow to ischemic sites. Placental growth 
factor (PLGF) is a key arteriogenic growth factor. Interestingly, studies have shown that 
PLGF is downregulated in people with type II diabetes, potentially contributing to 
impaired collateral artery growth. However, how diabetes affects PLGF expression is not 
well defined. Advanced glycation end products (AGE) and inflammatory cytokines such 
as tumor necrosis factor-α (TNFα) have been implicated in vascular pathology. We 
therefore hypothesized that AGE-TNFα signaling would impair PLGF expression in 
endothelial (EC) and/or skeletal muscle cells (SKMC). To test this hypothesis, human 
coronary artery EC and SKMC were treated with AGE, bovine serum albumin (BSA, as a 
control for AGE), or TNFα. AGE had no direct effect on PLGF in EC and SKMC. 
However, TNFα reduced PLGF in EC (P<0.001) but had no effect on PLGF levels in 
human and mouse SKMC.  In order to determine whether AGE might influence PLGF in 
EC or SKMC through a macrophage-mediated effect, RAW 264.7 murine macrophages 
was treated with AGE or BSA. RAW media was then transferred to murine endothelial 
cells (EOMA). Treatment with both RAW-BSA and RAW-AGE media significantly 
reduced PLGF levels in EOMA cells, compared with control RAW media (P<0.001). 
Interestingly, ELISA analysis showed that TNFα was increased in RAW-AGE media, but 
not in RAW-BSA media or RAW-control media (P<0.0001). Analysis of RAW media 
using a multiplex mouse cytokine assay confirmed that TNFα was increased in RAW-
AGE media compared to RAW-BSA and RAW-control media (P<0.007). We conclude 
that AGE may act to reduce PLGF expression in EC via a macrophage-mediated 
mechanism involving induction of inflammatory cytokine secretion. These new insights 
have the potential to lead to future therapies to improve collateral growth in patients with 
type II diabetes.  
v 
 
TABLE OF CONTENTS 
 
Chapter          Page 
 
I. REVIEW OF LITERATURE .....................................................................................1 
  
 Overview of the Cardiovascular System..................................................................1 
 Cardiovascular Disease ............................................................................................5 
 Atherosclerosis .........................................................................................................6 
 Causes/Risk Factors of Atherosclerosis ...................................................................7 
 Innate/Genetic/Environmental Factors ....................................................................7 
 Age ...........................................................................................................................8 
 Endothelial Dysfunction/Inflammation ...................................................................8 
 SMC Proliferation and Migration ............................................................................9 
 Plaque formation and Rupture .................................................................................9 
 Coronary Artery Disease........................................................................................10 
 Peripheral Artery Disease ......................................................................................12 
 Therapeutic Angiogenesis/Arteriogenesis for PAD...............................................15 
 Therapeutic Angiogenesis/Arteriogenesis for CAD ..............................................16 
 Coronary Collateral Circulation .............................................................................18 
 Arteriogenesis vs Angiogenesis .............................................................................21 
 Exercise and Arteriogenesis ...................................................................................22 
 Signaling Pathways ................................................................................................23 
 Cell Types  .............................................................................................................25 
 Endothelial Cell .....................................................................................................25 
 Smooth Muscle Cells .............................................................................................28 
 Skeletal Muscle Cells .............................................................................................30 
 Diabetes..................................................................................................................32 
 Type I .....................................................................................................................32 
 Type 2 ....................................................................................................................33 
 Gestational Diabetes ..............................................................................................33 
 Effect on Endothelial Function ..............................................................................34 
vi 
 
Chapter          Page 
 
 Effect on Arteriogenesis ........................................................................................37 
 Placental Growth Factor (PLGF) ...........................................................................42 
 Advanced Glycation End Products (AGE) ............................................................51 
 Monocytes ..............................................................................................................55 
 Inflammation ..........................................................................................................61 
 Advanced Glycation End Products (AGE) and Inflammation ...............................62 
 
 
II. MATERIALS AND METHODS ............................................................................66 
 
 Human Primary Cells .............................................................................................66 
 Established Cell Lines............................................................................................66 
 Advanced Glycation End Product (AGE) Preparation  .........................................67 
 Treatment of Cells..................................................................................................68 
 Enzyme-Linked Immunosorbent Assay (ELISA) ..................................................69 
 RT-PCR..................................................................................................................69 
 Mouse Multiplex Cytokine Assay .........................................................................70 
 Statistical Analysis .................................................................................................70 
 
 
III. RESULTS ..............................................................................................................73 
 
 AGE had no direct effect on PLGF expression .....................................................73 
 Recombinant TNFα reduced PLGF protein levels in HCAEC but had no effect 
on HSKMC and MSKMC……………………………………………………………………………..73  
 Recombinant IL-1 treatment had no significant effect on PLGF protein levels in 
HCAEC ..................................................................................................................74 
 Direct effect of AGE on TNFα stimulation in EC and SKMCs ............................74 
      AGE increased TNFα protein levels in murine macrophages ...............................74  
 AGE treated Macrophage media increased TNFα production in Endothelial cells 
while AGE and BSA-treated Macrophage media both reduced PLGF in EC .......75 
 Endothelial cells pre-incubated with AGE and activated with inflammatory   
mediators increased TNF@ Expression………………………………………….75 
 TNFα was most abundantly produced by AGE activated RAW macrophages, 
followed by IL-10 and IFN-Y ................................................................................76  
 Stimulation of murine EC (EOMA) with LPS further decreased PLGF ...............76 
 Direct AGE treatment of HCAEC had no significant effect on ICAM-1, VCAM-1, 
TNFα, MCP-1 and RAGE mRNA .........................................................................76 
 TNFα mRNA was not significantly affected in RAW-AGE Treated Media and 
RAGE-mRNA is downregulated in activated RAW Media ..................................77 
 MCP-1, RAGE and TNFα were insignificant in EOMA cell incubated with AGE-





Chapter          Page 
 
IV. DISCUSSION ........................................................................................................98 
 
 Effect of AGE treatment on PLGF expression in EC and SKMC .........................99 
 Effect of AGE treatment on TNFα expression in EC and SKMC .........................99 
 Effect of AGE treatment on TNFα and PLGF expression in RAW 264.7 cells ..101 
 Effect of Recombinant TNF@ and IL-1 Treatment on PLGF expression EC 
        and SKMC .........................................................................................................102 
 Effect of RAW 264.7 conditioned media on PLGF expression in EOMA …….103  
 Effect of Endothelial cell activation on Responsiveness to AGE………..……..105  
      Mouse Multiplex Cytokine Assay .....................................................……… … 106 
 Gene Expression for markers of endothelial cell and macrophage activation.....108 
 Possible Mechanism.............................................................................................109 
 Future Studies ......................................................................................................110 
 Limitation of the Study ........................................................................................111  
Clinical Implications ............................................................................................111 
 
 
V.  CONCLUSION ....................................................................................................113 
 




LIST OF TABLES 
 
 
Table           Page 
 




LIST OF FIGURES 
 
Figure           Page 
 
   1 Structure of the artery wall ......................................................................................3 
   2 Illustration of key features in neovascularization ..................................................18 
   3 Flowchart depicting important events in arteriogenesis ........................................30 
   4 AGE had no direct effect on HCAEC ....................................................................79 
   5 AGE had no direct effect on PLGF mRNA ...........................................................80 
   6 AGE had no direct effect on HSKMC but had an effect on MSKMC ..................81 
   7 Recombinant TNF@ decreased. PLGF levels in HCAEC ....................................82 
   8 Recombinant TNF@ in HSKMC and MSKMC ....................................................83 
   9 IL-1 had no significant effect on PLGF in HCAEC ..............................................84 
   10 AGE increased TNF@ in macrophages ...............................................................85 
   11 RAW media treated with AGE significantly increased TNF@ in EOMA cell ...86 
   12 TNF@ mRNA was not significantly different between EOMA cells incubated .88 
   13 RAW media treated with BSA or AGE decreased PLGF levels in EOMA .. 89-90 
   14 TNF@ is overexpressed in HCAEC pre-incubated with AGE and activated .....91 
   15 TNF@ cytokine is most secreted by RAW 264.7 murine macrophages .............92 
   16 AGE did not directly activate endothelial cells mRNA gene expression ...... 93-94 
   17 AGE may not signal through the RAGE receptor in RAW 264.7 .......................95 
   18 AGE indirect effect on EC does not affect gene translation .......................... 96-97 













LIST OF ABBREVIATION 
CVD Cardiovascular diseases 
CAD Coronary artery disease 
PAD Peripheral artery disease 
EC Endothelial cells 
MI Myocardial infarction 
PLGF Placental growth factor 
VEGF-A Vascular endothelial growth factor-A 
AGE Advanced glycation end products 
LDL Low density lipoprotein 
VEGFR Vascular endothelial growth factor receptor 
SMC Smooth muscle cells 
VSMC Vascular smooth muscle cells 
QF Quadriceps femoris 
G-P-S Gastrocnemius/plantaris/soleus 
ECM Extracellular membrane/matrix 
NO Nitric oxide 
MAPK Mitogen activated protein kinase 
ICAM-1 Intracellular adhesion molecule 
VCAM-1 Vascular cell adhesion molecule 
NF-κB Nuclear factor-kappa B 
JNK Jun amino-terminal kinases 
ERK Extracellular 
RAGE Receptor for advanced glycation end products 
MCP-1 Monocyte chemoattractant protein-1 
TNFα Tumor necrosis factor-α 
FGF Fibroblast growth factor 
CCL Chemokine C-C motif ligand 
CD Cluster of differentiation 
DM Diabetes mellitus 
NADPH Nicotinamide adenine dinucleotide phosphate hydrogen 
ALI Acute limb ischemia 




GLUT Glucose transporters 
BM-MNC Bone marrow mono nuclear cells 
EPC Endothelial projenitor cells 
EOMA Mouse hemangioendothelioma endothelial cells 
xi 
 
HCAEC Human coronary artery endothelial cell 
SKMC Skeletal muscle cells 







REVIEW OF LITERATURE 
 
Overview of the Cardiovascular System 
The cardiovascular system is made up of the heart and the circulatory system. The 
heart serves as a pump that ejects blood out to the organs, tissues and cells of the body. The 
blood being pumped contains oxygen and nutrients that is then delivered to every cell. 
Carbon dioxide and waste product made by those cells are in turn removed by the blood 
for excretion [1]. 
The process of circulation is made possible by a complex network of blood vessels. 
Blood rich in oxygen is taken away from the heart to the body by arteries and arterioles 
until it reaches the capillaries, and the oxygen depleted blood is then returned back to the 
heart by venules and veins. As the name implies, in the circulatory system, blood is pumped 
out and back to the heart in a closed circuit, flowing through all these vessels again and 
again [2]. 
There are two circulatory systems in the human body that operate in series. The 
systemic circulation supplies oxygen and nutrients to the body cells. It also transports 
disease fighting substances throughout the body, carries hormones from glands to  
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organs, and delivers waste to the kidneys. The pulmonary circulation delivers 
deoxygenated blood to the lungs where inspired O2 is exchanged for CO2, which can then 
be expirated, and returns oxygenated blood to the heart [3]. 
As in the fully grown adult, survival of a developing embryo depends on the 
circulation of blood to maintain homeostasis and the cellular environment, which accounts 
for the reason why the circulatory system makes its appearance early in embryogenesis and 
attains a functional level even before other major organ in the body. That small formed 
heart begins to beat as early as the fourth week after fertilization. 
The heart as a pump is muscular to be able to generate the pressure force needed to 
circulate the blood and ensure it reaches all the tissues in the body. The heart muscle (the 
myocardium) therefore, in other to survive, needs a continuous supply of nutrients and 
oxygen and removal of its metabolic waste. Without this, heart cells soon go through 
irreversible changes that can lead to cell death. When the heart muscle is damaged, the 
heart may lose its pumping effectiveness. Depending on the severity of the damage, loss of 
heart function for even a few seconds can compromise life. 
Blood is supplied to the myocardium by the right and left coronary arteries, which 
branches from the ascending aorta. Blood passes through the capillaries of the 
myocardium, enters a system of coronary (cardiac) veins which drains into the coronary 
sinus, and is returned to the right atrium.  
Blood is ejected from the ventricles into the aorta and the large elastic arteries that 
branch off from it. The wall of an artery consist of three layers (Figure 1). The innermost 
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layer is called the tunica intima or tunica interna. It is made up of simple, squamous 
epithelium (endothelial cells) and surrounded by a connective tissue basement membrane 
with elastic fibers. The middle layer is the tunica media, primarily made up of smooth 
muscle; this is the thickest layer. It gives support for the vessel and it is also the region 
that changes in diameter to regulate blood flow and pressure. The outermost layer is the 
tunica externa or tunica adventitia. It attaches the vessel to the external environment. It is 
made up of connective tissue with varying amounts of elastic and collagenous fibers. The 
connective tissue in the tunica externa closer to the tunica media is quite dense while the 
tissue closer to the periphery is loose. 
 
 
Figure 1. Structure of the artery wall. This illustration shows the component of the artery wall the 





The capillaries, the most abundant of the blood vessels, form the connection 
between the arteries and the veins. Capillaries are the site at which O2, CO2, nutrients, 
and waste products are primarily exchanged between blood and tissue. Therefore, 
capillary distribution reflects the metabolic activity of a particular tissue. Tissues such as 
skeletal muscles, liver and kidney have abundant capillary networks because they are 
metabolically active and require an abundant supply of oxygen and nutrients. Other types 
of tissue, such as connective tissue, have fewer capillaries. The lens and cornea of the 
eye, and the epidermis of the skin, do not have a capillary network [3]. 
Veins carry blood from the capillaries back to the heart. Veins have the same three 
layers as the arteries, but contain less smooth muscle and connective tissue. This makes the 
walls of veins thinner than those of arteries, and they operate at lower pressures than 
arteries. Because the walls of veins are more easily stretched by pressure than the walls of 
arteries, the veins typically contain more blood than the arteries at any given time. 
In order to understand the movement of blood through the circulatory system, there 
is a need to differentiate between blood flow, pressure, rate or velocity, and resistance. 
Movement of blood through the vessels is termed blood flow. Blood flow rate is the volume 
of blood passing through the vessels per unit of time. A force is exerted by the heart to 
cause the blood to flow through the vessels. The measure of that force is the blood pressure. 
Blood, like other fluids, moves from an area of high pressure to one of low pressure. Thus 
blood flow rate is directly proportional to the pressure gradient (pressure difference 
between beginning and end of a vessel). Blood flow velocity is the distance traveled by 
blood per unit of time. Blood flow velocity is inversely proportional to the total cross-
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sectional area of the blood vessel it is flowing through. The larger the area, the slower the 
flow velocity. Thus, blood moves slowest in the capillaries (which have the largest cross 
sectional area in the circulation) and fastest in the arteries (which have the smallest cross 
sectional area in the circulation). Resistance is the force that opposes the flow of blood, 
and it is primarily related to vessel diameter [4]. The smaller the vessel diameter, the greater 
the resistance, and the less the flow. By the time the blood is leaving the capillaries and 
moving into the veins, only a small amount of the pressure applied by the heart remains. 
Blood flow through the veins back to the heart is not pulsatile and is facilitated by skeletal 
muscle action, respiratory movements, and constriction of smooth muscle in the venous 
walls. 
Cardiovascular Disease 
Cardiovascular disease in general refers to processes that leads to narrowing or 
blockage of blood vessels, which eventually culminates in a heart attack, chest pain 
(angina) or stroke. Other conditions that affect the heart rhythm, heart valves, and heart 
muscles are also part of heart disease. Cardiovascular risk factors include a high body mass 
index (BMI), large waist circumference, high blood pressure and lipids, elevated levels of 
inflammatory markers/adhesion molecules, and diabetes [5]. Cigarette smoking is another 
important risk factor for cardiovascular disease. 
Cardiovascular disease (CVD) is a cause of immense health and economic burden 
in the United States and even globally [6]. Heart and circulatory disease conditions include 
stroke, subclinical atherosclerosis, congenital heart disease, rhythm disorders, coronary 
artery disease (CHD), heart failure (HF), valvular disease, venous disease and peripheral 
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artery disease [7]. The World Health Organization estimates that CVD will cause the death 
of 23.6 million people by the year 2030 [8]. 
According to the American Heart Association (AHA) and the Centers for Disease 
Control and Prevention (CDC), heart disease is the number one cause of death in America, 
followed by cancer [6]. Approximately 17.6 million deaths were caused by cardiovascular 
disease globally in 2016, which is an increase of 14.5% from deaths in 2006. Coronary 
heart disease is the leading cause of death associated with CVD (43.2%) followed by stroke 
(16.9%), high blood pressure (9.8%), diseases of the arteries (3%), and other minor 
cardiovascular diseases combined (17.7%). Of the 840,678 deaths recorded in 2016 in 
America, 635,260 deaths were from coronary heart disease. About 610,000 people die 
every year of heart disease and about 735,000 people living in America have heart attacks 
every year. Altogether, cardiovascular disease costs the US about $200 billion every year 
[9]. 
Atherosclerosis 
Atherosclerosis is a chronic inflammatory disease and is said to be the leading cause 
of coronary artery disease, peripheral artery disease and stroke [10] and the resultant deaths 
[11], resulting from loss of elastin, increasing accumulation of lipids, cholesterol and 
infiltration of additional cells. This pathological remodeling is as a result of repair 
responses of the arterial wall cells to the stress factors and injuries it experiences. 
Atherosclerosis affects medium and large arteries, and  many cells types are involved in 
the development and progression of atherosclerosis, including endothelial cells (EC), 
smooth muscle cells (SMC), and inflammatory cells [12]. The SMC take on a synthetic 
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phenotype (as opposed to their normal contractile phenotype), and begin to migrate from 
the tunica media to the tunica intima (inward migration instead of the outward migration 
that happens in vessel growth).  There is also increased synthesis of extracellular matrix 
fibers, calcification of the vessel wall, foam cell formation, and deposition of cholesterol-
containing lipid. These processes are accompanied by inflammation of the SMC and 
increased migration of inflammatory cells and lymphocytes. Altogether, these events result 
in the formation of lesions in the intima called plaques, which consist of cholesterol or its 
esters covered by a fibrous cap. Plaque formation causes a mechanical obstruction in the 
bloodstream which alters blood flow patterns and can also cause formation of a thrombus 
(blood clot). As the lesion develops, the plaque can rupture, initiating platelet 
adhesion/activation and the formation of a thrombus, which occludes blood flow through 
the artery and causes organ dysfunction [13].  
Causes/Risk Factors of Atherosclerosis 
 
Innate/Genetic/Environmental factors 
One might assume that atherosclerosis is a result of modern day dysregulation in 
lifestyle, but it is interesting to know that atherosclerosis dates back to at least 4000 years 
ago [14]. Studies of embalmed mummies have shown atherosclerotic lesions and 
calcifications in their arteries, suggesting that the causes of atherosclerosis also include 
innate, genetic, and environmental factors. Various forms of infection that prevailed in the 
premodern era may have contributed to promoting atherosclerosis as much as chronic, 
systemic inflammatory diseases do in today’s human beings. Likewise, smoke inhalation 
from open flames can contribute to atherosclerosis just as well as cigarette smoking [15]. 
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Genetic variations associated with increased susceptibility to atherosclerosis and 
cardiovascular disease also play a role [16-19].  
Age 
Evidence suggests that atherosclerosis starts of at an early stage in life and 
progresses as the individual ages. With repeated cycles of damage and local healing of the 
arterial wall occurring over a person’s lifetime, age can be said to be the most common risk 
factor for atherosclerosis. However, research has shown that early forms of diet-type 
atherosclerosis may be reversible; that is, startup of a new lifestyle of a low-fat diet or 
taking of lipid-lowering drugs despite age, can reduce fatty deposits of plaque in the artery. 
This reduction is possible as a result of the breakdown of lipids in the plaques, infiltration 
of macrophages, and a differentiation of macrophages from the proinflammatory M1 to the 
anti-inflammatory M2 type [20].  
Endothelial Dysfunction/Inflammation 
Atherosclerosis begins with a response-to-injury-type of mechanism [21]. At first, 
the endothelium is intact, but when a micro-injury occurs, it leads to endothelial 
dysfunction characterized by increased permeability, increased secretion of adhesion 
molecules, and alterations in gene expression. Endothelial dysfunction has been shown to 
affect more than 100 genes in different signaling pathways, depending on the type of initial 
stimulus [22]. However, hypercholesterolemia is the major cause of EC dysfunction at the 
beginning of atherosclerosis. Initially, cholesterol crystals were thought to be passive in 
atherosclerosis, but their role as active triggers of atherogenic inflammatory response is 
now well established [23]. Chronic hypercholesterolemia or hyperlipidemia causes 
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accumulation of lipoproteins, which are then oxidized by locally produced reactive oxygen 
species to form oxidized low-density lipoproteins (LDL) and oxidized cholesterol esters 
which in turn stimulate the production of cytokines, chemokines and growth factors by EC 
and contribute to recruitment of monocytes [24]. In addition, disturbed shear stress patterns 
are a trigger for the development of atherosclerosis. These patterns naturally occur at 
branching sites of larger arteries. Therefore, atherosclerosis is more likely to occur at 
arterial branching sites [25].   
SMC Proliferation and Migration 
The secretion of growth factors, chemokines and cytokines from the macrophages 
and EC changes the SMC to a synthetic phenotype, which functions differently than its 
contractile phenotype in a healthy vessel. The SMC start to proliferate and migrate from 
the media to the intima. This leads to a formation of a mature atherosclerotic lesion (fibro-
atheroma), in which there is continuous production and deposition of extracellular matrix 
(collagens and proteoglycans). Additionally, macrophages and SMC within the lesion 
phagocytose oxidized lipoproteins, including cholesterol crystals released by cell death, 
causing the formation of foam cells. This process causes a fresh release of cytokines that 
maintains the activation of macrophages and causes recruitment of other leukocytes 
including T lymphocytes. The end result is a chronic, continuous inflammatory situation 
[26, 27]. 
Plaque Formation and Rupture 
It is worthy to note that as long as the necrotic core of cholesterol crystals and the 
calcification around it are enclosed by SMC and ECM proteins (the fibrous cap), then the 
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plaque remains in a stable state. Nevertheless, the continuous cycle of foam cell formation, 
production of matrix metalloproteinases that degrade the matrix proteins around the 
lesions, infiltration and recruitment of other immune cells, and death of SMC, can all lead 
to the rupture of the fibrous cap. If the cap ruptures, all these necrotic and inflammatory 
particles are then released into the bloodstream. This can lead to thrombosis and occlusion 
of other blood vessels, resulting in ischemia and associated cardiovascular events. 
Thus, overall, atherosclerosis is established as a specialized inflammatory disease 
with some possibly immune mediated component [28-30]. 
Coronary Artery Disease (CAD) 
CAD, as noted above, is the leading cause of morbidity and mortality amongst all 
the diseases of the cardiovascular system and is the leading cause of death in the United 
States. It results from pathological changes within the coronary artery walls that lead to 
plaque buildup and breakup, causing thrombosis and reducing blood flow. Clinically, 
patients with coronary artery disease often present with chronic chest pain or discomfort 
known as angina pectoris. Angina is the most common symptom of CAD because when 
the blood vessels do not get enough blood (myocardial ischemia), the first sign is chest 
discomfort or pain. In more advanced cases, patients may present with acute coronary 
syndrome (ACS) which can be manifested as acute angina, acute myocardial infarction 
(AMI; heart attack) in which a portion the heart muscle is deprived of blood and dies [31], 
or even sudden cardiac death.  
There are three mechanisms by which arterial occlusion occurs in CAD. The first 
is vascular spasm of coronary arteries. This may even occur at the early stages of 
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atherosclerosis and happens when the damaged blood vessel constricts. The smooth muscle 
around the artery has a spasm (sudden contraction) which narrows the vessel and prevents 
oxygen and nutrients from being delivered to the heart muscle. Vasodilator medications 
may be able to treat this type of acute occlusion, and the disease process itself may still be 
reversible at this point, for example, if an unhealthy diet is replaced by a low-fat and -
sodium diet. This type is brought on by physical examination. The second mechanism of 
arterial occlusion is due mainly to atherosclerotic plaque forming under the vessel lining, 
with a lipid core surrounded by an overgrowth and proliferation of smooth muscle and 
collagen deposition. This plaque bulges into the vessel lumen, causing partial to full 
occlusion and limiting blood flow. The plaque can also become calcified, “hardening” the 
artery. The third mechanism of arterial occlusion in CAD is thromboembolism, where 
breakdown of the plaque triggers platelet aggregation and clot formation (thrombosis) 
and/or a clot entering the circulation and lodging in a different vessel (embolism). 
Currently, the best treatment for coronary heart disease is stent implantation. 
Various types of stents have been developed and used but the effect is not always 
permanent [32-35]. For over more than a decade, extensive studies have been performed 
to describe vascular responses to implanted stents of various type and to show what 
correlates to the pathobiology evidenced at the stent placement sites. [36]. Adverse reaction 
to stents is caused by many factors including stent characteristics, individual susceptibility 
determined by genetic predisposition, procedural factors, clinical factors, and 
inflammatory response. Thus, there is need for improved therapeutic interventions so as to 
achieve desired clinical outcomes [36] 
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Peripheral Artery Disease 
The peripheral vascular system is that part of the circulatory system that transports 
blood and nutrients to the extremities (arms, legs, hands, and feet). Peripheral artery disease 
(PAD) causes narrowing of the arteries that supply the extremities, limiting blood flow to 
the skeletal muscles (especially the lower limbs). This reduced blood flow causes a range 
of clinical symptoms [37]. According to the National Health and Nutrition Examination 
survey (NHANES) in the United States, PAD affects more than 8.5 million adults, which 
accounts for ~12-20% of people above 60 years of age [6]. The number of deaths in 
America attributable to PAD in 2016 was 56,923 while globally, about 202 million people 
were living with PAD in 2010. That was an increase of 23.5% (164million in 2000 to 
202million in 2010) [38].  
Since atherosclerosis is a systemic disease, there happens to be a strong association 
between coronary artery disease, peripheral artery disease, and cerebrovascular disease.  
The clinical severity of one of these syndromes in a patient predicts the presence of the 
others. PAD is therefore a marker for systemic atherosclerotic disease, meaning that people 
with PAD are more likely to have atherosclerosis in other vascular beds (coronary, cerebral, 
and others) [39]. PAD is a strong predictor of death from vascular causes; the worse the 
severity of PAD in a patient, the more likelihood there is for death of the patient due to 
myocardial infarction or stroke. Patients who show symptoms of large vessel PAD have a 
25% chance of death due to vascular disease within 12 months, and the mortality rate of 
patients with severe, chronic PAD is as high as 45% of all cases [40, 41]. Although PAD 
is thus a strong marker for vascular disease, it is unfortunately under-recognized and under-
treated [42, 43]. Patients have no symptoms in almost half of all cases of PAD, and there 
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is no universal screening program in existence in most developed countries. Preventive 
measures to prevent the occurrence of PAD was advocated in the United States in 1999-
2006 but was only adhered to by 24-35% adult patient [44] 
Risk factors for PAD are the same as those for atherosclerosis in general, and 
include smoking, high blood pressure, hypercholesterolemia/hyperlipidemia, diabetes 
mellitus, obesity, and a family history of vascular disease. Out of these factors, smoking 
and diabetes are the strongest markers of the risk for mortality and morbidity from PAD 
[45]. In patients with a confirmed diagnosis of PAD, diabetes has been shown to increase 
amputation and mortality rates [46]. It also correlates with increased atherosclerosis 
development and accelerated rates of cardiac events, especially in patients with poor 
glucose control [47].  
Diagnosis of PAD is made clinically by using the ankle brachial index (ABI) or by 
the use of imaging [ultrasound, computed tomography (CT), or magnetic resonance 
imaging (MRI)]. ABI is a ratio of blood pressure measured at the brachial artery (in the 
arm) to that measured at the dorsalis pedis (posterior tibial artery in the leg). Essentially, 
the index is calculated by taking the blood pressure at both the upper and lower limb and 
averaging it. Peripheral artery disease is then diagnosed if the ABI < 0.9. PAD is identified 
as mild in cases where the ABI is between 0.7-0.9, moderate in cases where ABI is between 
0.5-0.7, and severe when the ABI is <0.5. ABI serves to indicate how severe the disease is, 
and also helps to monitor the progress of existing disease and any response to initiated 
treatments [48]. Vascular imaging techniques may be used for diagnosis of PAD in 
symptomatic individuals or in those whose ABI is abnormal for other reasons. It can 
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identify arterial obstruction in specific vascular sites and also help to demonstrate degree 
of stenosis, and can be used for assessing the effectiveness of treatment.  
PAD is clinically classified into four groups based on symptoms: asymptomatic, 
intermittent claudication (IC), chronic limb ischemia (CLI) or acute limb ischemia (ALI). 
The asymptomatic group represents over 50% of patients with PAD and these are the ones 
that mostly go unrecognized and undertreated by their primary care physicians [49]. 
Though they look unaffected and still go about with daily functions and activities, they 
actually have a 40% risk for stroke, and a 20-60% risk for MI higher than in people without 
PAD [50]. The next group of patients, the intermittent claudication (IC) patients, is said to 
be the classic type of PAD patient. IC comes with itching pain in the calves, thighs, or 
buttocks, which the patient feels during activity but subsides at rest. It can also manifest as 
cramping in the lower legs, and may cause limping. Though it may significantly limit the 
quality of life, IC is generally stable. With time, only 1-3% of IC patients will require 
amputation [51, 52]. However, the presence of any of the risk factors mentioned above 
increases the risk of amputation. The third group of patients has chronic limb ischemia 
(CLI), which is defined as pain even when the patient is at rest, or by the presence of ulcers 
with or without tissue necrosis. These patients mostly have an ABI <0.5 and as such, may 
require amputation. Almost 25% of CLI patients will undergo amputation within one year 
of diagnosis.  They have 1, 5, and 10 year mortality rates of 20-45%, 40-70%, and 80-95% 
respectively [53]. Finally, in the last group of patients with ALI, there is a sudden onset of 
limb ischemia which threatens limb viability. It is seen as increasing claudication and 
progresses quickly to pain even at rest. These patients experience what is known as the six 
P’s of acute limb ischemia (pulselessness, pallor, poikilothermia, paraesthesia and 
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paralysis). ALI is caused by atherosclerotic plaque rupture and the resulting occlusive 
thrombus which is formed and blocks blood flow to the limb. In contrast to CLI, the 
obstruction happens so quickly that it does not allow for the formation of collateral vessels, 
hence limb viability is compromised. ALI requires prompt revascularization by means of 
thrombectomy or catheter-directed thrombolysis with a drug such as urokinase. 
Unfortunately, many times all attempts to save the limb still result in amputation in about 
10-15% of cases, and there is a 12 month mortality period in such patients [54]. 
There are several currently accepted treatments for PAD. Some patients may be 
helped by lifestyle modification one such example is exercise therapy. Some other options 
for patients with more severe disease or those who cannot exercise are using drugs to 
dissolve clots, surgical removal of clots, angioplasty or stent placement to widen blocked 
vessels, and bypass surgery. In a bypass surgery the blood is diverted around the blocked 
area by grafting a vessel taken from elsewhere in the body. Despite the fact that these 
treatments are effective in many patients, they have various drawbacks and are not effective 
in all patients. That explains the need to develop new treatments for PAD [55]. 
Therapeutic Angiogenesis/Arteriogenesis for PAD 
Finding a way to induce therapeutic angiogenesis/arteriogenesis has long been an 
important goal for PAD treatment. This process occurs in response to tissue ischemia and 
inadequate blood supply brought about by occlusion in the large vessels, and results in 
structural alteration in existing small collateral vessels to enable them to enlarge and 
function like a natural bypass. An increase in collateral growth 
(angiogenesis/arteriogenesis) would therefore bring about an effective solution for the 
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PAD burden [56]. Genetic and stem cell therapy to stimulate angiogenesis/arteriogenesis 
are potential approaches to PAD treatment. The use of growth factors in the treatment of 
PAD first began to be investigated about 20 years ago. Various angiogenic and arteriogenic 
growth factors stimulate blood vessel growth and can be administered as recombinant 
proteins intraarterially or intramuscularly to promote growth of collateral circulation [57].  
Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor showed 
some promise in early studies, but gave indefinite results in a much larger clinical trial 
testing [58, 59]. These results suggested the problem was more complicated than just a lack 
of growth factors. Collison et al put it this way: “impaired responsiveness to angiogenic 
stimuli…..rather than a problem with the availability of angiogenic growth factors” was 
the reason for the indefinite results. Other studies have investigated hematopoietic stem-
cell transplant as a possible treatment, with research evidence showing that administration 
of these bone marrow derived progenitor cells promotes new blood vessel formation via a 
paracrine effect and leads to improvement in ABI by releasing pro-angiogenic growth 
factors and cytokines that causes blood vessel radial growth in patients with PAD.  
Therapeutic Angiogenesis/Arteriogenesis for CAD 
Similarly to PAD, CAD can be treated in a variety of ways, including by 
percutaneous coronary intervention (PCI; angioplasty and stenting), coronary artery bypass 
grafting (CABG), and by medical treatment to manage underlying disease processes such 
as diabetes and atherosclerosis. However, development of new and promising therapeutic 
processes that offer better options is needed. There has been a rise in the number of people 
for whom angioplasty and stenting is not fully effective.  A prevalence of 25.8% of 
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incomplete revascularization has been documented, with impaired quality of life and 
increased mortality at three years for these patients as compared to patients with complete 
revascularization [60]. There has also been an increase in “no-option” patients (patients 
who cannot undergo PCI or CABG and who despite medical therapy, still suffer from the 
effects of coronary artery disease).  
As discussed above, the body in itself can create vascular bypasses from naturally 
existing anastomoses. This is a noninvasive process and can prevent tissue ischemia by 
getting blood across to areas that are distal from the site of occlusion. Stimulation of this 
process of arteriogenesis may present a better therapeutic approach than current clinical 
interventions [61]. Improved coronary collateral circulation has been proven to increase 
survival in patients with CAD, therefore, there have been many studies conducted on 
interventions aimed at promoting a well-developed collateral circulation [62]. A better 
understanding of the mechanical factors and the signaling pathways that initiate and control 
arteriogenesis may identify new targets for treatments to promote the formation of these 





Figure 2. Illustration of key features in neovascularization. Modified from Jose Mann-
Garcia 2007 Post-Genomic Cardiology 
Coronary Collateral Circulation 
Vasculogenesis is the process of development of the cardiovascular system during 
embryogenesis, where de novo formation of blood vessels occurs from endothelial 
progenitor cells (EPC) [64]. These EPCs sprout out to form dense vascular networks, with 
various anastomoses. This network is at its peak at birth, but declines as time goes on by 
physiological regression, a process called pruning. The remaining collaterals recede in 
caliber or size and have little blood flow moving through them under normal conditions. 
However, with changes in vascular pressure and resistance, they can again be recruited. 
This is often the case in the cause of CAD, where there is the development of a pressure 
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gradient across a stenotic lesion. This pressure gradient causes an increase in flow through 
these preformed arterial anastomoses/collateral arteries, and leads to a structural 
remodeling process termed arteriogenesis. Thus, it can be said that the development of fully 
functional coronary collaterals depends on the presence of CAD, and that collateral 
development is highest when there is a total coronary occlusion [62]. 
Without coronary atherosclerosis, coronary collaterals in patients are in the range 
of 10-200uM caliber, but in patients with CAD, there can be a four-fold increase and 
collaterals may be 100-800uM in diameter. This observation was confirmed in an 
experimental model, where occlusion of the femoral artery in rabbits increased the vascular 
diameter of pre-existing collaterals by four- to five-fold [65]. 
Interestingly, there are species-to-species variations in naturally existing 
collaterals. Humans have been found to have them, but there are variations in number from 
individual to individual. Guinea pigs have the most abundant naturally existing collaterals, 
with reports that those collaterals in a guinea pig are enough to compensate for blood flow 
during stenosis of a major coronary artery. Dogs and cats have also been shown to have 
well-developed coronary collaterals while rabbits, baboons, and rats have less [66, 67]. The 
precise basis for these differences between species is not known and is a very interesting 
question for comparative studies. 
Collaterals are networks of arterial to arterial blood vessel connections in between 
vascular branches [77]. Ordinarily, they have very small radius which makes blood flow 
through them difficult due to high resistance. But in pathology (atherosclerosis) of a major 
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coronary artery, they undergo radial remodeling and act as alternative bypass to overcome 
the resultant induced ischemia. 
Arteriogenesis, an outward remodeling of the collateral wall, progresses in three 
stages. The first stage, known as the initiation stage, starts with the release of chemokines, 
upregulation of adhesion molecules, and changes in the ECM. The second stage is called 
the growth phase and features the recruitment and infiltration of leukocytes (particularly 
monocytes), EC and SMC migration, and an increase in the radius of the lumen and length 
of the vessel, making it tortuous. The infiltrating monocytes produce a variety of growth 
factors that contribute to these processes in the growing blood vessel.  Finally, in the third 
stage, maturation and stabilization of the vessel takes place, and the SMC return to their 
contractile phenotype as opposed to the synthetic phenotype they adopt during vessel 
growth [68]  
Normally, in a non-growing collateral, vascular smooth muscle cells are arranged 
in a circular and regular structure. However, during the remodeling, the basement 
membrane disappears. The SMC then begin to migrate to the sub-endothelial layer after 
adopting a secretory phenotype characterized by prominent rough endoplasmic reticulum, 
golgi and mitochondria (this is different from their usual contractile phenotype with 
abundant α-smooth muscle actin and few organelles). They also loose desmin, an 
intermediate filament protein. This disintegrate the collagen basal matrix and enable 
smooth muscle cell proliferation, widening the diameter. When the remodeling is complete, 
SMC goes back into its contractile state [69, 70]. This event is very similar to the smooth 
muscle cell proliferation that occur in atherosclerosis but that causes an inward migration 
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of the smooth muscle cells and causes a decrease in arterial wall diameter, reducing 
pulsatile flow of the arteries. This happens chronically but arteriogenesis is actually a 
controlled process to restore blood flow and is self-limiting as soon as the process is 
complete. The collaterals disappear as soon as blood flow is restored to the distal parts of 
the occlusion [70, 71]. 
Arteriogenesis vs. Angiogenesis 
There is a need to differentiate between angiogenesis and arteriogenesis. Both occur 
in the adult and cause vascular growth. Angiogenesis is the sprouting of capillaries formed 
from the existing vascular network. These capillaries elongate and sprout to give rise to a 
more dense capillary network. Angiogenesis is thought to be primarily hypoxia-induced 
and VEGF-driven. Hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth 
factor (VEGF) have been shown to be key contributors to angiogenesis. Angiogenesis is 
therefore mainly driven by metabolic demands of the tissue for oxygen [72-74]. Whereas 
capillary sprouting may decrease the diffusion distance for O2 within a particular tissue, it 
cannot increase the overall amount of blood reaching tissues that are distal to occluded 
sites, because tissue blood flow is controlled at the level of the arterioles. Therefore, 
angiogenesis is not effective at increasing tissue perfusion [75].  
Arteriogenesis, on the other hand, is a type of vascular growth that entails the 
remodeling of naturally preexisting arterioles, allowing for an overall increase in blood 
flow to the affected tissue. Unlike angiogenesis, arteriogenesis is regulated by mechanical 
stimuli and pro-inflammatory signaling pathways rather than hypoxia. It can be seen that 
hypoxia is not a major influence in arteriogenesis, because there is a long distance between 
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the occluded region where the collateral arteries are remodeling, and the hypoxic region 
which is the distal tissue that is being under perfused [76]. Atherosclerotic occlusion drives 
the adaptive response of arteriogenesis to compensate for lack of blood flow to distal 
regions of the tissue. Blood is diverted from the blocked vessel into collaterals, causing a 
change in blood flow and shear stress. The increased shear stress serves as the initial trigger 
for arteriogenesis to begin. The increase in fluid shear stress  causes an increase in a variety 
of factors including nitric oxide, PLGF [77] and monocyte chemoattractant protein-1 
(MCP-1), resulting in attraction and recruitment of monocytes [63, 68].  
Interestingly, arteriogenesis shares many common mechanisms with 
atherosclerosis (a chronic inflammatory disease). Treatments to stimulate arteriogenesis 
are therefore potentially prone to cause harmful effects in what is termed a “Janus 
Phenomenon” [74, 78]. This could be one reason why many studies that focused on 
monocyte activation as a potential treatment, though initially promising, could not be 
translated into clinical settings [69, 79-82]. The benefit to risk ratio was unbalanced and 
these researches were discontinued. This is an important consideration for developing 
future therapies to stimulate arteriogenesis. 
Exercise and Arteriogenesis 
Arteriogenesis has been shown to be induced in humans as well as animals through 
exercise training. Exercise increases blood flow to the cardiac or skeletal muscle, altering 
the fluid shear stress (FSS) in the collateral vessels in the skeletal muscles, which activates 
the process of vascular remodeling and diameter growth [83-87]. It has also been shown to 
suppress inflammation and activities of proinflammatory immune cells and to improve 
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endothelial function [88-90]. Although exercise is clearly helpful, questions remain, such 
as what type and duration of exercise are effective to induce collaterization (especially in 
patients with limited physical abilities). In addition, the arteriogenic effect seems to be 
transient and disappears after the exercise program is terminated. Exercise is also time 
consuming, which serves as a discouragement to many patients [62]. Nevertheless, exercise 
has been recommended by the European Society of Vascular Surgery (ESVS) as a 
treatment guideline for patients with peripheral artery disease [91].  
Signaling Pathways 
Research shows that arteriogenesis is an active process in which the cells of the 
vascular wall multiply (as opposed to the vessel just dilating passively).  
Mechanical forces such as altered shear stress in the collaterals are the primary 
stimulus for arteriogenesis [76]. Cell surface receptors on the EC of the arterioles sense 
this change in shear stress and transduce this signal into the cell to cause changes in its 
function through various signaling pathways. Through these pathways, transcription 
factors that control the expression of growth factors such as vascular endothelial growth 
factor (VEGF-A) and placental growth factor (PLGF) are activated. Shear stress has been 
shown to increase the levels of these growth factors [77]. Growth factors stimulated the 
endothelium and cause it to enter the cell cycle. Likewise, smooth muscle cells start to 
proliferate and produce metalloproteinases (MMPs) which breaks down the basement 
membrane and collagen, allowing SMC to migrate into the tissues [76]. Eventually, the 
cell mass of the vessel can increase to about 50 times its initial weight and its total diameter 
can increase to about 20 times its original diameter  [92].  
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Activated EC also increase their expression of genes that serve as chemoattractant 
for circulating cells (especially monocyte chemoattractant protein-1, MCP-1), and 
upregulate the expression of adhesion molecules and surface receptors (such as selectins, 
VCAM-1, and ICAM-1) that bring about the rolling and tethering of leukocytes (especially 
monocytes) followed by their migration out into the adventitial space [93] Monocyte 
adherence to the vessel wall and their subsequent differentiation into macrophages is a very 
important part of the arteriogenic process. Monocytes produce numerous cytokines, growth 
factors and proteases that help further destroy the basement membrane to allow smooth 
muscle cell migration. They also phagocytize surrounding cells, making way for the growth 
of arterioles [94]. 
Chemokine receptor 2 on circulating monocytes binds to the MCP-1 on the surface 
of activated EC, which begins a signaling cascade of events leading to the production of 
many cytokines, including bFGF and TNFα. TNFα has been shown to cause increased 
collateral density and conductance and has several actions on EC and monocytes. The 
TNFα produced by monocytes upregulates the expression of adhesion molecules both on 
the EC and monocytes, and upregulates granulocyte macrophage colony stimulating factor 
(GM-CSF), which helps prolong the lifespan of the monocytes. Monocytes have been 
shown to line the remodeling collateral artery within 12 h after arteriogenesis is initiated 
by ligation of an upstream artery, but to disappear over time [65]. Monocytes have also 
been shown to respond to the chemoattractant effect of PLGF, an important arteriogenic 
factor that brings about more infiltration of monocytes into the vessel wall [95]. 
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There are many growth factors that have been shown to stimulate angiogenesis and 
arteriogenesis. Of these, one of the best known is vascular endothelial growth factor 
(VEGF) which is critical in controlling endothelial function. Transforming growth factor 
(TGF-α, TGF-β), GM-CSF, MCP-1, FGF-2, and platelet–derived growth factor (PDGF) 





The endothelium is composed of endothelial cells (EC), which play an important 
role in maintaining normal vascular function. ECs are about 10-20μm in diameter, are flat, 
and cobble–like shaped with central nuclei. The entire vascular system is lined by a single 
layer of endothelial cells, with about ten trillion cells forming an almost 1kg organ (heart 
and blood vessels) in an adult. The endothelium acts as a semi-permeable barrier between 
the blood and tissues, hence it controls the passage of macromolecules [96].  Endothelial 
cells were once thought to be inert, but are now known to be active and wholly involved in 
homeostasis, immune, and inflammatory reactions. They produce and respond to different 
cytokines and adhesion molecules. It is now also clear that they can have both anti- and 
pro-inflammatory responses, depending on environmental cues, and that they are major 
immunoreactive cells.   
26 
 
When there is no disease present, the normal function of the endothelium is to 
maintain homeostasis, regulate vascular permeability, transport molecules (nutrients, 
oxygen, waste) between the blood and surrounding tissues, and maintain an 
atheroprotective environment in the blood stream through production of nitric oxide (NO) 
and other molecules. EC also release various vasoactive compounds (including NO, 
prostacyclin, and endothelin) that cause vasodilation or vasoconstriction of smooth 
muscles, thereby regulating the amount of blood flow into various organs in the body. 
These vasoactive substances released also prevent platelet aggregation and adhesion, hence 
creating a non-thrombotic environment and allowing the continuous and steady flow of 
blood [97-99]. However, endothelial dysfunction or activation can occur, and contributes 
to many diseases. An uncontrolled endothelial cell response gives rise to many disease 
states, such as atherogenesis, sepsis, hypertension and inflammatory syndromes. All these 
diseases are signs of endothelial injury, activation and dysfunction.  
In response to pro-inflammatory and procoagulant scenarios, EC can develop an 
imbalance in oxidative signaling (oxidative stress). There is a decrease in nitric oxide and 
an increase in reactive oxygen species (ROS) as a result of increased degradation of nitric 
oxide and decreased eNOS expression [100, 101]. Cardiovascular risk factors such as 
hypercholesterolemia, diabetes mellitus, hypertension and smoking contribute to this 
effect. This is because persistent hyperlipidemia and hyperglycemia generate increased 
ROS, which leads to increased oxidative stress on the endothelial cells. Two common 
forms of ROS, superoxide and hydrogen peroxide, are produced by vascular cells through 
several oxidases (NADPH and xanthine oxidases) and by uncoupling of the mitochondrial 
respiratory process from oxidative phosphorylation. Reactive oxygen species activate EC 
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to cause increased permeability and synthesis of inflammatory cytokines and adhesion 
molecules, as discussed below. 
In the healthy endothelium, junctional proteins and integrins help to maintain its 
integrity and play a major role in regulating its permeability, signal transduction, cell 
growth and survival. Intracellular junction proteins connected to the actin filaments of the 
EC cytoskeleton create strong cell-cell adhesion [96, 102, 103].  Integrins act as receptors 
for subendothelial extracellular matrix proteins such as fibronectin. They help to attach the 
endothelial cell monolayer to the extracellular matrix. This attachment of integrins to the 
extracellular matrix and intercellular junctions determines endothelial integrity, because 
lack of it results in increased vascular permeability [104]. Some other important proteins 
that help create the adhesions and tightness of the endothelial cell layer are occudins, 
claudins, adherins, and connexins. PECAM (platelet endothelial cell adhesion molecule) is 
also constitutively expressed on endothelial cells.  However, under pathological conditions 
such as oxidative stress, EC become activated and these normal structures and activities 
become impaired. Increased vascular permeability can be seen as a result. Increased 
endothelial permeability causes lipoproteins to accumulate within the sub endothelial space 
[105, 106]. In this way, EC activation leads to the pathogenesis of many cardiovascular 
diseases.   
Endothelial cells are exposed to blood flow and shear stress. It has been shown that 
EC are sensitive to shear stress variations, that is, changes in shear stress are then converted 
to intracellular signals that cause altered gene expression leading to structural and 
functional changes (vascular remodeling). Therefore, in the setting of atherosclerotic 
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vascular disease, EC also participate in the vascular remodeling process by downstream 
signaling that leads to the production and release of growth factors such as VEGF and 
PLGF [107], which induces arteriogenesis to maintain blood flow to distal sites following 
an upstream vascular occlusion [108]. 
Smooth muscle cells 
Smooth muscle cells make up the second and thickest layer of the vascular wall, 
the tunica media. It is the region that gives strength to the vessel and allows it to change in 
diameter to regulate blood flow. Arteriogenesis involves the differentiation, growth and 
migration of vascular smooth muscle cells (SMC) and remodeling of the extracellular 
matrix after infiltration of leukocytes (monocytes) and release of growth factors such as 
MCP-1 and PLGF. 
Formation of a thick new intima through a phenotypically changed and proliferating 
smooth muscle cell is a significant characteristic of a growing collateral vessel. During 
arteriogenesis, the vascular smooth muscle cells change from the contractile phenotype to 
the synthetic phenotype after the destruction of the basal membrane by proteases moves 
outwardly [109, 110]. At this step of arteriogenesis, there is a loss of SMC structural 
proteins, especially desmin [111]. With the switch from the contractile to the synthetic and 
proliferative phenotype, VSMC migrate through the internal elastic lamina into the lumen 
of the preexisting collateral vessel. Smooth muscle cells are thus primarily responsible for 
the outwardly remodeling pattern of collateral growth. In atherosclerosis, smooth muscle 
cell migration is an inward remodeling process, while in arteriogenesis, it is an outward 
remodeling process. As discussed above, there are many similarities between atherogenic 
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and arteriogenic signaling; therefore, the mechanism for this bidirectional switch has not 
fully been characterized. The smooth muscle cells regain their contractile phenotype as the 
collateral growth reaches completion [64]. 
An explanation of the relationship between the VSMC phenotype and 
arteriogenesis has only recently been shown by a study in which a ten-fold increase in 
smooth muscle contractile proteins (smooth muscle-MHC and smooth muscle α-actin) 
correlated with vascular smooth muscle cell proliferation and successful collateral growth 
in response to arterial occlusion in healthy animals and further showed no such correlation 




Figure 3. Flowchart depicting events in arteriogenesis, resulting in smooth muscle cell 
proliferation and collateral growth. Adapted from Post-Genomic Cardiology 2007. 
 
Skeletal Muscle Cells 
 
Skeletal muscles are specialized contractile muscles found in animals and are 
responsible for movement of the body. They are made up of muscle fibers and surrounded 
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with protective membranes. This makes them contract and move easily without much 
friction. Skeletal muscle cells are connected at their ends to the skeleton by tendons. These 
tendons are connected directly to the collagenous outer covering of the skeletal muscle, 
known as epimysium. Under the collagenous outer covering, skeletal muscles are grouped 
into bundles called fascicles, which are again covered by another protective covering made 
from collagen, the perimysium. This allows nerve and blood vessels to run through the 
muscles.  
Skeletal muscles make up approximately 40% of total body mass, making them the 
largest tissue in the body. They play a major role in movement and metabolism. Skeletal 
muscle mass and function are directed in response to changes in nutrition, physical activity, 
and the environment and disease conditions.  Blood from the heart is supplied to skeletal 
muscles by major arteries (peripheral arteries) and maintenance of their function is a key 
public health issue as reduction in function leads to unwanted clinical outcomes like poor 
glycemic control, impairment of bodily movement, reduced mobility, and mortality [112, 
113]. 
Arteriosclerotic plaques can form in peripheral arteries, leading to reduced blood 
flow to the skeletal muscles (peripheral artery disease) [114]. Although revascularization 
by surgical intervention may be possible for some patients, patients with critical limb 
ischemia, do not have the option of revascularization due to extreme tissue damage and 
prolonged atherosclerotic disease. Skeletal muscles have been said to be the tissue most 
vulnerable to ischemic damage in the extremities [115]. Hence, there is a need to develop 
new tissue rescue strategies to preserve skeletal muscles from ischemia. In arteriogenesis, 
collateral arteries in the skeletal muscle remodel to increase their diameter. Skeletal muscle 
32 
 
produces growth factors such as VEGF, PLGF, and MCP-1 [116],  although our lab has 
shown that the quantities of PLGF produced by skeletal muscle cells is less than that 
produced by endothelial cells. Skeletal muscle blood vessels are the main sites for 
arteriogenesis in peripheral artery disease, since the occlusion caused by atherosclerosis 
happens upstream in the major peripheral arteries. Therefore, studies on arteriogenesis 
using observations from skeletal muscle are very relevant in showing interactions between 
growth factors and their receptors and the corresponding radial collateral growth [117]. 
Diabetes 
 
Diabetes mellitus is a chronic metabolic disease that affected about 171 million 
people in the world in the year 2000, and is predicted to affect about 366 million by the 
year 2030 [118]. In the year 2012, about 29.1 million people in America had diabetes, and 
another 8.1 million people were prediabetic (not aware they were at risk for diabetes), thus 
allowing more damage to be done to their health. Diabetes is a disease that has resulted in 
both human and economic loss. Diabetes is primarily characterized by hyperglycemia 
(persistent high blood glucose), leading to the cells of the body being exposed to excess 
glucose for a long period of time (both in the cytoplasm and extracellularly). It has been 
classified into three types: type 1, type 2 and type 3 (gestational diabetes).   
Type 1 
 
Type I diabetes is also known as juvenile or insulin-dependent diabetes. It is a 
situation where the beta cells of the pancreas that secrete insulin die as a result of an 
autoimmune disease process where the body attacks itself, thus making the cells no longer 
able to make insulin. Therefore, this means endogenous insulin is not present and the 
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person has to take synthetically made insulin to keep their glucose level under control. 
Insulin is the key that stimulates the release of glucose transporters that are then able to 
bring glucose from the blood into the cell.  
Type 2 
 
Type 2 diabetes mellitus is also known as non-insulin dependent or insulin resistant 
diabetes. The beta cells of the pancreas make insulin, but the issue is that the cells are not 
sensitive to the insulin; hence, there is no movement of glucose transporters to the cell 
surface to bring in glucose. Therefore, glucose builds up in the blood. This situation is 
called insulin resistance, since insulin is present but there is resistance to the insulin-insulin 
receptor interaction that otherwise activates intracellular signaling to cause translocation 
of the GLUT (glucose transporters) to the cell surface where they can act as carriers of 
glucose into the cell. Insulin resistance is a result of a feedback mechanism that results after 
a long period of high insulin production by the pancreatic cells into the bloodstream leads 
to a decreased sensitivity to insulin.  
Gestational Diabetes 
 
Gestational diabetes, the third type of diabetes, is pregnancy-induced. High blood 
sugar, obesity, unhealthy eating habits and hereditary factors are possible causes of 
gestational diabetes during pregnancy. Babies born during to mothers with gestational 
diabetes are sometimes premature, or may become obese and are at higher risk of 




Effect on Endothelial Function 
 
Under normal physiological conditions, endothelial cells have stable interactions 
with the underlying smooth muscle cells, have scanty organelles, and contain a flat nucleus. 
They are in turn separated from the connective tissue underneath them by a thin 
extracellular matrix called the basal lamina. In addition, the EC are actively carrying out 
transcytosis, a process of transcellular transport across the endothelium. 
The structure of the endothelial cells and their extracellular matrix is compromised 
in the presence of hyperglycemia. In hyperglycemia, there is an increase in the number of 
organelles such as the Golgi body and rough endoplasmic reticulum. The basal lamina 
begins to thicken, leading to impairment in metabolic transport between the blood and 
tissues. Diabetes also causes endothelial barrier injury, resulting in hyperpermeability and 
plasma leakage, an important feature of endothelial dysfunction [119]. 
In normal endothelial cells, specific transport systems move essential circulating 
blood macromolecules across endothelial cells to the subendothelial layer to meet the 
metabolic demand of the underlying tissue, while tight junctions (located in between 
endothelial cells) work as selective barriers to regulate the movement of molecules from 
circulation. The GLUT gene family transports glucose across the endothelial cells. Of this 
family, only GLUT-1 and GLUT-4 are expressed by endothelial cells [120]. The former is 
the most expressed, while the regulation of GLUT-4 expression is important in diabetes 
and hypoxemia.   
Hyperglycemia is an important factor that leads to endothelial cell dysfunction. 
Chronic hyperglycemia in diabetes is a major factor in the development of both macro- and 
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micro-vascular disease. A study reported that treatment of human endothelial cells with 
25mM glucose resulted in upregulation of several inflammatory genes, including IL-8 and 
ICAM-1 [121] 
Although diabetes mellitus leads to alterations in nearly every organ and cell type 
in the body, one of the most dramatic effects is on the endothelium, where diabetes leads 
to endothelial dysfunction and cardiovascular disease. Five main hypothesis have been put 
forward by different researchers to explain how diabetes causes endothelial cell 
dysfunction and vascular complications. These include 1) increased polyol pathway flux; 
2) increased advanced glycation end-product (AGE) formation; 3) activation of protein 
kinase C isoforms; 4) increased hexosamine pathway flux; and 5) increased formation of 
reactive oxygen species and other products of abundant oxidative stress. For the purposes 
of this discussion, we will focus on AGE. 
Advanced glycation end products (AGE), are formed as a result of modification of 
proteins and lipids and are found in pathological settings including hyperglycemia. When 
they bind to enzymes, they sometimes affect the physiological activity or even totally 
inactivate it. The importance of AGE formation especially in vivo started to be recognized 
in the 1970s with studies on HbA1c, a naturally occurring small human hemoglobin type 
that is increased in diabetic patients. HbA1c is a post translational product formed when 
glucose reacts with the N-terminal valine amino group of the b-chain of hemoglobin. It is 
used as a marker for assessing metabolic indices in diabetic patients and reflects the average 
blood glucose concentration for a 60-120 day period [122]. AGE found in the diabetic 
tissues have been found to cause the destabilization of the extracellular matrix. AGE 
formation is associated with alteration of homeostasis in DM. Intracellular molecules 
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modified by AGE leads to impairment in growth factor functions [123]. In endothelial cells 
exposed to high amount of glucose, intracellular AGE has been seen to form within a week. 
bFGF is one of AGE modified growth factors in EC. Thus, bFGF loses its ability to fully 
stimulate EC due to its glycation and cannot induce angiogenesis [124]. The receptor for 
AGE, RAGE, have been shown to be expressed at low levels in the adult in different cell 
types including EC, macrophages, lymphocytes, VSMC, podocytes and neurons [125] But 
a significant increase in RAGE expression is caused by diabetes mellitus [125, 126] with 
increased AGE ligands in the blood and tissues. This report shows the relationship between 
RAGE expression and its ligand AGE in the diabetic blood, as well as that of RAGE 
expression in circulating cells and resultant increase in ligand levels in that circulation 
[127-129]. In EC, SMC and monocytes, ligation of RAGE causes activation of ras21, 
MAPK signaling pathway and GTPases, which in turn, results in transcriptional activation 
by NFkB, and other factors [130]. Increased expression of adhesion molecules on EC and 
monocytes such as VCAM, ICAM and E-selectin follows. Apart from transcriptional 
activation of various adhesion molecules, RAGE ligation also leads high expression of 
proinflammatory cytokines IL-1, IL-6, tumor necrosis factor-α [131]. Some of these are 
known to induce RAGE transcription. Therefore, there is a resultant increase in cellular 
adhesiveness in DM and hyperglycemia.  
Compared with those of similar age groups, diabetic patients often present with 
more widespread atherosclerotic disease, more severe atherosclerotic lesions and larger 
number of occlusions. This is because diabetes is linked to endothelial dysfunction hence; 
it increases the progression of atherosclerotic disease. Endothelial dysfunction is easily 
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observed and detected in young patients who presents with early signs of insulin resistance 
with or without other types pf cardiovascular risk factors. 
Endothelial dysfunction is a complex process that leads to an imbalance in the 
production and degradation of biological mediators of normal body function. Increase in 
oxidative stress is one such imbalance. Normally, reactive oxygen are produced to help to 
accomplish some functions in the body and thereafter broken down by certain oxidants into 
nontoxic substances. In diabetes, there is increased production and decreased breakdown 
of these reactive oxygen species hence leading to damage and alterations in cellular 
activities. NADPH oxidase is an enzyme that donates an electron to oxygen, leading to the 
formation of superoxide (ROS), which in turn is converted to hydrogen peroxide (H2O2), 
another ROS, in the presence of superoxide dismutase.  Catalase then finishes the 
degradation by breaking down hydrogen peroxide to oxygen and water but in an immune 
cells, for example neutrophil that contain phagosome that destroys and engulfs foreign 
materials, hydrogen peroxide is converted to hypochlorous acid and water in the presence 
of myeloperoxidase and chlorine in the neutrophil to enhance phagocytosis. 
Pharmacological inhibition of these enzymes resulted in overproduction of ROS.  
Effect on Arteriogenesis 
 
Diabetes mellitus has been shown to be a negative predictor of collateral growth 
[132] [133]Variations shown by different individuals in the extent of arteriogenesis suggest 
that the presence of an additional disorder may cause a suppression of the innate ability to 
develop new vascular growth in response to occlusion. Diabetic patients with coronary 
disease were studied with non-diabetic patients having similar disease. The former were 
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shown to have reduced arteriogenesis [134] . This may be the cause for high mortality rates 
in diabetes-associated coronary and peripheral artery disease. The mechanism by which 
this occur is still under investigation and is not fully characterized.  
The severity of coronary artery and peripheral artery diseases in diabetic patients 
have been linked to an impaired or altered process of arteriogenesis [135, 136].  
Assessment of this impaired mechanism in diabetic patients have been limited to the 
descriptive imaging of collaterals as shown with the use of angiography or magnetic 
resonance imaging type of angiography, collateral blood flow and resistance invasive 
assessment, based on either temporary or chronic coronary artery occlusion and collateral 
flow measurements and pressure [137, 138]. These studies casted some lights on the 
intrinsic mechanisms causing impairment in vascular growth in diabetes.  
Further studies on effect of diabetes on collateral growth (arteriogenesis) were 
further illustrated from studies on functional abilities of circulating cells that are essentially 
involved in arteriogenesis. These includes monocytes, lymphocytes and endothelial 
circulating cells. It was shown that monocyte response is impaired in an ex vivo analysis 
[136, 139] Monocytes from diabetic patients cannot move towards VEGF-A, a relevant 
arteriogenic growth factor. This show a functional defect in the downstream signaling as 
the kinase function of the receptor, VEGFR-1, was not affected. This reduction in 
monocytes migration was also seen with other types of growth factors involved in 
arteriogenesis process [140, 141] 
Most documented report on impairment of collateral artery growth resulting from 
diabetes mellitus are from animal studies. Other reports are also from cell culture in vitro 
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studies of the different pathophysiological reasons for diabetes-arteriogenic derailment.  
These studies show that growth factors and their receptors are affected in terms of 
production and expression; extracellular matrix and other cells that contributes to collateral 
growth are also affected in same manner. Therefore, the resultant effect of diabetes on 
arteriogenesis is as a result of defects in arteriogenic growth factor signaling (reduced 
perception, promotion and interpretation of arteriogenic signal or stimuli [136] 
Early evidence that revealed that diabetics may have an inadequate or reduced 
arteriogenesis was a study of autopsied hearts of diabetes with a history of myocardial 
infarction. Their vessels reveal on examination intimal layers with endothelial 
proliferations and focal bulges that narrowed the walls. There was also increased arterial 
wall thickness due to fibrosis and mucopolysaccharide accumulation that altered the elastic 
fibers. In patients without DM, arterial wall thickness was observed with increase in vessel 
diameter but these were both decreased in the diabetics [142] 
Another mechanism by which diabetes have been shown to adversely affect 
arteriogenesis is by elevated production of antiangiogenic factors. Angiostatin, can go 
against the expression of arteriogenic growth factors and cause reduced blood vessel 
growth. It is a product of the breakdown of plasminogen by matrix metalloproteinases 
(MMP-2 and MMP-9). These two are activated when there is oxidative stress or reduced 
nitric oxide production in vitro. It is also produced by diabetic blood vessels in vivo.  




As shown earlier, current interpretations for impaired preexisting collateral growth 
indicates that this is not only based on existing vascular cells found in the vessels but also 
on circulating cells. Diabetes and hyperglycemia causes endothelial cell dysfunction[145] 
and so counteracts the rescue mechanism for cardiovascular ischemia. Monocyte function 
is adversely affected by diabetes. A very important characteristic of monocyte is their 
ability to migrate towards a created gradient of growth factors or cytokines whenever that 
is present (called chemotaxis). In a study where freshly isolated monocytes from diabetic 
subjects were isolated, there was total reduction of monocytes to VEGF-A compared to a 
strong migration towards an inflammatory mediator tripeptide fMLP. CD34+ cells from 
the diabetic did not also migrate to growth factor VEGF but displayed cytoskeletal rigidity 
due to reduced nitric oxide signaling [146]. Monocytes from type 1 diabetic subjects also 
did not trans-migrate towards proinflammatory CCL2 and CCL3 [147]. Circulating cells 
from diabetic patients are in an activated status [148], which is replicated by exposure of 
these cells to hyperglycemia in cell cultures. Significant increase in transcription factors 
are observed, but displayed a tumor necrosis factor (TNFα) induced adhesion of the 
circulating cells to EC. Upregulation of cell surface adhesion molecules were also 
observed, which increases monocyte adhesion but there is generally a reduction in trans-
endothelial migration towards growth factor (reduced chemotaxis). Hyperglycemia and 
diabetes causes the activation of several signaling pathway, hence increase in markers of 
activation and adhesion molecules. The resultant effect of this is that it makes vascular 




There is also evidence of reduced blood vessel growth in diabetics from studies that 
showed glycation of growth factors, glycation of extracellular matrix proteins that reduces 
proteolysis and hence affect smooth muscle proliferation and growth in expanding the 
vascular diameter. bFGF, a growth factor, was glycated following exposure to 
hyperglycemia reduced its high heparin binding and mitogenic activity. It also lowered its 
migration towards the EC. This also continued even when it was injected into normal 
glycemic mice. The glycated bFGF displayed less angiogenic effect than the non-glycated 
bFGF [124] Advanced glycation end products (AGE) have also been implicated in diabetic 
reduced arteriogenesis. As shown in a mouse hind limb model, due to AGE deposition, 
angiographic imaging showed a reduced blood perfusion in the ischemic leg. This was 
revered by amino guanidine, a substance that inhibit AGE formation , which decreased the 
amount of AGE been formed and restored impairment in arteriogenesis AGE has been 
shown to prevent matrix degradation due to its accumulation and amino guanidine restored 
the process [150]. 
Studies on bone marrow mononuclear cells (BM-MNC), also revealed the effect of 
diabetes on collateral growth. There was a decrease in proangiogenic response, which was 
shown by a reduced capacity of the diabetic BM-MNC to differentiate into endothelial 
progenitor cells and also by reduced angiogenic function in cultured cells. Placental growth 
factor (PLGF), belonging to the VEGF family, was able to reverse this impaired function 




Placental Growth Factor (PLGF) 
 
Placental growth factor (PLGF) was discovered in 1991 by an Italian scientist, 
Maria Graziella Persico. She cloned and purified the protein and characterized its structure 
by crystallography. She also was able to identify VEGF receptor-1 (VEGFR-1) as its 
receptor, and thus classified it as one of the members of the vascular endothelial growth 
factor (VEGF) family. She worked along with Dr. Peter Carmeliet in Leuven, Belgium, to 
show evidence that PLGF is actually quiescent in postnatal growth, but very necessary in 
vascular embryonic development. PLGF is expressed abundantly in the placenta but is 
increased elsewhere in several pathological states [152]. Besides the placenta, PLGF is also 
expressed in vascular endothelial cells, smooth muscle cells, the heart, skeletal muscle, and 
activated inflammatory cells [116, 153]. In comparison to VEGF-A, PLGF is only 
expressed in certain tumor cell types [154]. Human PLGF is composed of four isoforms, 
which are derived after the primary transcript undergoes alternative splicing. PLGF 1-4 
differ in size, in how they are secreted, and in binding attributes. PLGF 1-3 bind to VEGFR-
1, which is mainly expressed on the EC cell surface, while PLGF 2 binds VEGFR-1 and 
also neuropilin-1 and -2 (which are also expressed on EC); this is heparin-dependent 
binding. PLGF-4, the last isoform, also has a heparin binding domain [155]. In the mouse 
genome, only one isoform of PLGF is seen, which has a 65% similarity to the human 
PLGF-2 isoform [156] 
PLGF is an N-glycosylated secretory protein and exists mainly as a homodimer but 
can also form heterodimer with VEGF. Its structure contains six cysteine residues within 
each monomer that form three disulfide bridges, creating a three-dimensional shape called 
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a cystine-knot. Cysteine residues of each monomer also form two inter-linked disulfide 
bonds to make up the homodimer. So each homodimer express two cysteine-knot at 
opposite ends of the PLGF molecule. Even though the human isoform of PLGF has only a 
42% amino acid sequence resemblance to VEGF-A, its three-dimensional shape is 
comparable to that of the latter [157]. The PLGF dimer contains two α-helices and seven 
β-sheets per each monomer. If one of the two glycosylated ends of the PLGF molecule is 
mutated, then the binding ability can become reduced which shows that unlike VEGF-A, 
glycosylation is very important in PLGF receptor binding ability [155]. 
The angiogenic/arteriogenic properties of the VEGF family of growth factor are 
mediated by their binding and activation of two tyrosine kinase receptors, VEGFR-1 and 
VEGFR-2. These two receptors have seven immunoglobulin-like domains that are 
expressed extracellularly. They also have a transmembrane and intracellular domain, the 
latter having tyrosine kinase activity. When a ligand binds to the extracellular domain, 
receptor dimerization takes place, followed by phosphorylation. Though PIGF shares a 
three-dimensional conformational structure that resembles that of VEGF-A, it has the 
ability to bind solely to VEGFR-1 receptor [158] with more affinity than VEGF-A or 
VEGF-B. The immunoglobulin-like domain 2 of VEGFR1 is the site of primary binding 
of PLGF, VEGF-A and B [159, 160], but PLGF and VEGF-A can also bind to domain 3 
on the VEGFR-1 receptor.  Binding to domain 3 is more important for PLGF than VEGF-
A, since it has been shown that deletion of domain 3 only causes a 50% decrease in VEGF 
receptor binding, but a 500% decrease in PLGF binding [161]. 
Though PLGF binds primarily to VEGFR-1, it can indirectly activate VEGFR-2, 
by binding to VEGFR-1 and throwing off VEGF-A, making it available to bind VEGFR-2 
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[162]. Another indirect way PLGF can activate VEGFR-2 is if both PLGF and VEGF-A 
coexist in the same cell, they may form a heterodimer [163].This heterodimer form can 
bind and activate VEGFR-1 and then stimulate a VEGFR-1/VEGFR-2 dimerization, once 
the two receptors are upregulated on the surface of the cell [164]. Furthermore, one report 
shows that when PLGF is the first to bind to the VEGFR-1 receptor, a transphosphorylation 
of the VEGFR-2 receptor can occur to cause its activation as well [165]. VEGFR-1 (Flt-1) 
is needed in the first stages of embryonic vascularization and gene knockout results in death 
in the embryo [166]. Even though endothelial proliferation appeared normal in the 
knockouts, dysregulated vascular formation was still observed when the receptor was 
deleted. 
In angiogenesis, when both PLGF and VEGF co-exist, it has been shown that PLGF 
potentiates the effect of VEGF in vitro and in vivo. When bovine adrenal cortex-derived 
capillary endothelial cells or human umbilical vein endothelial cells were exposed to both 
VEGF and PLGF, endothelial cell proliferation was 50-fold higher than with VEGF-A 
alone. This effect of PLGF to increase proliferation was only observed with VEGF-A and 
not with other growth factors, for example, bFGF. In vitro, heterodimer formation of 
VEGF/PLGF potentiated the mitogenic endothelial cell response, with more VEGFR-2 
binding and tyrosine kinase activation observed. Also, there was greater EC migration with 
heterodimers, compared with PLGF homodimers [158].  
PLGF does not directly promote angiogenesis (capillary proliferation) because it 
does not stimulate a mitogenic response in EC, but PLGF can increase the mitogenic 
response of capillary EC to VEGF. The combination of PLGF and VEGF has been shown 
to stimulate the growth of new capillaries 36 h earlier than treatment with FGF-2 alone, 
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illustrating that together they induce a faster growth of cells to form capillary endothelium 
[167]. Lack of PLGF has been shown to disrupt EC responses to VEGF but not to bFGF, 
which makes PLGF a kind of control switch for VEGF action [162]. In another experiment, 
PLGF was overexpressed in the skin by using a keratin-14 promoter. This caused an 
increase in the number of growing blood vessels. This was more evidence of PLGF’s strong 
arteriogenic property [168]. 
PLGF induces collateral growth more effectively than other growth factors such as VEGF 
and PDGF because it causes a stimulation of both EC and SMC at the same time, while 
VEGF modulates just the EC and platelet derived growth factor (PDGF) modulates just the 
SMC [169]. 
PLGF acts to potentiate the effect of VEGF by recruiting monocytes/macrophages 
[170]. It does this by causing an increase in the mRNA levels of interleukin-1β, interleukin-
8, MCP-1, and VEGF in peripheral blood mononuclear cells [171]. PLGF is involved in 
tumor angiogenesis by causing increased infiltration of circulating hematopoietic 
progenitor cells and also of macrophages to proliferating tumor vasculature [162]. In 
another experiment, PLGF directly increased the bone marrow recovery at the early stages 
of ligation by inducing an increased chemoattactiveness of VEGFR-1 bone marrow 
progenitor cells. In another mouse model, human PLGF was shown to act in synergy with 
human granulocyte colony-stimulating factor (GM-CSF) to increase the number of 
circulating hematopoietic blood progenitor cells [172]. In a diabetic wound closure 
experiment, it was shown that PLGF is needed for attracting monocytes and macrophages 
to the site of injury. PLGF was produced by infiltrating keratinocytes and by the endothelial 
cells of the collaterals. An absence of PLGF resulted in lack of wound healing.  PLGF was 
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also shown to cause increased adhesion of monocytes/macrophages to sites of collateral 
growth during an ischemic hindlimb experiment  
As discussed before, monocyte infiltration into the site of collateral growth is 
essential in arteriogenesis [173-175]. The importance of PLGF in arteriogenesis is 
evidenced by the discovery that PLGF has chemoattractant properties towards monocytes. 
Monocyte express only one type of VEGF receptor: VEGFR-1, which is the particular 
receptor of choice for PLGF to bind to [173]. Therefore, it is clear that there is an important 
biological role for PLGF and the VEGFR-1 receptor in human monocyte infiltration and 
activation. VEGFR-1/PLGF binding also stimulates smooth muscle cell growth, another 
process important in arteriogenesis, and causes an increase in the release of the arteriogenic 
cytokines TNFα and MCP-1 through recruitment of the monocytes/macrophages [176].  
Therefore, we can say that PLGF is an arteriogenic growth factor that acts primarily on 
monocytes while VEGF is angiogenic and acts primarily on endothelial cells [141, 176, 
177]. 
In tumor studies, PLGF was seen in hyper vascular renal cell carcinomas but not in 
the normal healthy kidney. VEGF expression was high in human primary thyroid tumors, 
but PLGF was low [178, 179]. High PLGF expression appears to be limited to certain types 
of tumors, such as breast and gastric tumors. Low PLGF in other tumors has been suggested 
to be due to methylation of the PLGF promoter region [180] 
In vivo, the decreased arteriogenic response to femoral artery ligation in PLGF 
knockout mice was recovered by administering exogenous PLGF. This rescue was 
associated with a PLGF-induced increase in monocyte number at the site of collateral 
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growth. Conversely, when pharmacological action was used to deplete the monocyte 
population before femoral ligation was carried out, PLGF mediated collateral growth was 
hampered. In another experiment in PLGF knockout mice, arteriogenesis was rescued by 
infusion of exogenous PLGF protein, but infusion of exogenous protein did not restore 
collateral growth if monocytes were depleted first [181]. Similarly, another study showed 
that impaired arteriogenesis in response to femoral artery ligation was due to deficient 
monocyte/macrophages in circulation. There was reduced blood flow 7 d after the ligation 
in monocyte/macrophage deficient mice in comparison to control mice that had normal 
levels of circulating monocytes. Immunohistology showed reduced monocyte infiltration 
at the site of collaterals [182].  
In an experiment in PLGF knockout mice, there was no visible defects in blood 
vessel growth at baseline. But when hindlimb ischemia or myocardial infarction was 
induced, evidence of a reduced arteriogenic response was observed. Increased collateral 
growth response to the ischemic insult was only observed in the wild type mice that had 
PLGF present, with tortuous and enlarged vessels providing evidence of an arteriogenic 
response to ligation. PLGF levels in the wild type had increased by about 45% after the 
ligation, resulting in infiltration and migration of monocytes. Interestingly, fibronectin (a 
glycoprotein of the extracellular matrix that provides a scaffold for migrating SMC) had 
extravasated or leaked in the wild type at a higher rate compared with the PLGF knockout 
where it only extravasated at 25%. This observation confirms that the presence of PLGF is 
essential for vascular permeability and plasma extravasation, an important process in 
arteriogenesis, to occur [162, 183] 
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 Increased expression of PLGF was also observed after an acute myocardial 
infarction that showed improved patient therapy as a result of increase in left ventricular 
ejection [184]. Therefore, a pharmacological intervention to improve PLGF expression or 
signaling will be a breakthrough strategy that will compensate for atherosclerotic stenosis 
by improving collateral growth and development [185]. 
In arteriogenesis, PLGF has been shown to more strongly induce the growth in size 
and increase in number of collateral arteries following femoral artery ligation compared to 
VEGF. This was evidenced by a 3-fold improvement in collateral growth with PLGF [176]. 
Also, knockout of the PLGF gene in a mouse model resulted in an impaired arteriogenic 
response in the knockout animals when compared to wild type in the situations of ischemia, 
wound healing and cancer, showing that PLGF is an important determinant of adaptive 
collateral vessel formation. This scenario was reversed by transplantation of bone marrow 
from PLGF positive mice, increasing circulating bone marrow progenitor cells induced by 
presence of PLGF [174]. 
Shear stress has been shown to be the main activator of arteriogenesis and therefore, 
our group hypothesized that shear would be the main regulator of PLGF expression in 
vascular cells. Co-culture experiments using human coronary artery endothelial and 
smooth muscle cells showed an elevation in PLGF mRNA and protein expression when 
the cells were subjected to high shear (mimicking the effect of a 60% occlusion in an 
upstream artery on shear stress in collaterals) [77]. 
Similarly, PLGF has been shown to be upregulated by mechanotransduction, as 
seen in an experiment where bronchial epithelial cells were exposed to stretch. PLGF and 
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nitric oxide were increased in a manner dependent on the amount of stretch and the duration 
[186]. In another study, when blood was withdrawn from human patients with chronic total 
coronary occlusion and CAD, more PLGF was seen at the distal coronary vessels. This was 
correlated to shear stress but not to duration of the occlusion [187]. 
PLGF mediated signaling has not been extensively studied. PLGF signaling in 
placenta and in HUVEC showed a difference in downstream components of the signaling 
mechanism although the upstream activation was the same [188]. In the former, VEGFR-
1 activation by PLGF was seen to induce stress activated kinase, JNK and p38 protein 
kinase, with a small induction of ERK1/2. However, in the latter, PLGF strongly induced 
ERK1/2 but had low effect on the JNK and p38 signaling pathways. This confirms that 
there is a difference in the downstream MAPK signaling even with the same upstream 
signaling (PLGF activation of VEGFR-1). This effect may be due to cell type-dictated 
influence [189] 
PLGF regulation has been shown to be affected by diabetes, though detailed 
characterization is yet to be described. Streptozotocin induced diabetic mice had abnormal 
PLGF expression in wounds. When PLGF was overexpressed by gene transfer, wound 
healing was restored in these diabetic mice. The improvement was a result of increased 
vascularization and monocyte/macrophage recruitment [190]. 
The infusion of growth factors has been considered as an alternative therapy to 
percutaneous revascularization. Vascular endothelial growth factor (VEGF) and fibroblast 
growth factor treatment have been shown to temporarily improve myocardial blood flow 
and function in experimental models, but clinical trials of their use were not successful. A 
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recent study examined whether PLGF might be able to induce revascularization without 
some of the negative side effects observed for VEGF. In this study, mice were fed a high 
cholesterol diet for 4 wks. and chronic myocardial ischemia was induced by transient 
ligation at 8 wk. Either recombinant PLGF-2 or vehicle was then randomly infused into 
the mice. The results showed an increased PLGF level in the plasma, without any negative 
systemic inflammatory or hemodynamic effects. Furthermore, there was no negative 
effects on atherosclerotic plaque growth, composition, or vulnerability as had previously 
been seen following VEGF infusion [191] and cell adhesion molecules were not 
upregulated by PLGF compared to vehicle. PLGF treatment significantly improved 
myocardial function and increased capillary and collateral density [192]. The researchers 
in this particular experiment used PLGF-2 because compared to PLGF-1; it has a heparin 
binding motif that confers an interaction with coreceptors neuropilin 1 and -2 on it, which 
makes for enhanced signaling and increased chemotaxis and sprouting of endothelial cells 
[193].  
A similar study conducted in pigs with chronic myocardial ischemia found that 
administration of recombinant PLGF-2 improved myocardial blood flow and function. In 
addition, there were no adverse effects observed. The lack of adverse effects is particularly 
important because other studies had shown an adverse effect of exogenous PLGF on early 
formation of atherosclerotic plaque and on carotid artery injury of rabbits 9 d after local 




Advanced Glycation End Products (AGE) 
 
As discussed earlier, advanced glycation end product (AGE) formation is one of 
the mechanisms by which diabetes hampers arteriogenesis. One aspect of the metabolic 
syndrome in diabetes is hyperglycemia, which is characterized by an excess level of 
glucose in the blood plasma for a long time. AGE, a heterogenous class of compounds 
formed from modified proteins and lipids and nucleic acids, are formed in the 
hyperglycemic state. Formerly, AGE was thought to only be formed outside the cell 
through a non-enzymatic reaction between glucose and the proteins that exist 
extracellularly, but now we know that AGE is also formed within the cells at a much greater 
rate [196]. The whole process starts with the Maillard reaction, in which the carbonyl group 
of glucose reacts with the amino group of another molecule (protein, lipids, nucleic acid) 
to form a Schiff base. This is formed within a few hours. This Schiff base can further 
undergo a rearrangement inside the molecule itself to form what is known as Amadori 
products, which are more stable. It takes several days to form an Amadori product. The 
Amadori product can further form irreversible products [197] or it may break down into 
various compounds. If it does not break down, it can begin to cross-link other proteins, 
eventually leading to the formation of AGE.  AGE formation on an enzyme may cause its 
complete inactivation (lack of function) since protein shape or structure correlates with 
their functions. Similarly, extracellular matrix proteins, when glycated, have impaired 
function and may not be easily broken down by proteolysis (an important process in vessel 
proliferation and growth). Carboxymethyllysine (CML) has been identified as the most 
abundant AGE in vivo due to its high degree of accumulation in tissues [198, 199].  
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High amounts of AGE in skeletal muscle and blood have been found to cause 
reduced muscle mass, reduced grip strength and movement in the elderly and in patients 
with diabetes mellitus [200-203]. This shows that there is a negative correlation between 
AGE and skeletal muscle function. This relationship was found to occur as a result of 
dietary consumption of foods rich in AGE. Foods cooked at high temperatures, high fat 
foods such as butter and sesame oil, and tobacco have all been found to contain AGE 
products which can be absorbed into the body through consumption [204, 205]. AGE are 
not well absorbed, so this had made the ill effect of dietary consumption go unnoticed for 
a while, but recently data collected from a randomized trial implicated dietary AGE as a 
cause of chronic diseases such as diabetes, CVD and chronic kidney diseases, which they 
promote by causing increased inflammation and oxidative stress [206]. When  a  reduced 
dietary intake of AGE-enriched foods was established, insulin resistance, endothelial 
dysfunction and oxidative stress was improved [207]. 
In an experiment on the long term effect of consumption of an AGE-rich diet on 
skeletal muscle function, mice were fed either a high AGE diet or a low AGE diet for 16 
wk. Mice fed the high AGE diet had less muscle mass, reduced skeletal muscle function, 
and the accumulation of a CML type of AGE product in the skeletal muscle [208]. 
AGE is associated with homeostatic imbalance in diabetes [209] where it causes 
extracellular cross-linking and alterations in the interactions between extracellular matrix 
and cells. On collagen, AGE cross-linking causes an expansion of the molecule, impairing 
its function as an intact barrier. It also changes the structure of the cell binding domain of 
type IV  collagen, decreasing endothelial cell adhesion [210]. AGE also leads to glycation 
of growth factors [123] and affects enzymatic signaling pathways (for example, production 
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of nitric oxide). AGE has been shown to decrease vessel wall elasticity in diabetic rats, and 
to cause a rise in fluid leaking across the vessel wall [211]. In all the above examples, the 
alterations caused by AGE were not due to specific interactions with cellular proteins. 
However, AGE has also been shown to interact with some cell-surface proteins that 
normally function in the removal or neutralization of AGE (for example, macrophage 
scavenger receptors) [212]. There are also receptors that can lead to modified gene 
expression when they interact with AGE [213, 214].  An important example of this is the 
receptor for AGE (RAGE), which has been much studied and has been shown to act as a 
signal transduction receptor [215]. 
The receptor for AGE, RAGE, was discovered as a cell surface receptor for AGE 
in cultured vascular cells from studies on diabetic complications [215] and RAGE was also 
found to be present on blood cells. Through this receptor AGE can interact with endothelial 
cells, peripheral blood-derived monocytes/macrophages and vascular smooth muscle cells. 
The effects of AGE can be reversed by treating cells with antibodies against the receptor 
or by the use of soluble RAGE, which is a decoy form of the RAGE receptor that possesses 
an extracellular domain but lacks the intracellular domain to cause downstream signaling 
[213, 214, 216-218]. Studies have shown that RAGE is expressed at low levels in different 
cell types including endothelial cells, macrophages, lymphocytes and vascular smooth 
muscle cells [125, 219], but diabetes causes an increase in RAGE expression [125, 126]. 
This is in line with increased AGE levels in the blood [220] and in the tissues as well [221, 
222]. This shows an overlap of RAGE/AGE interaction in diabetic blood vessels, as well 
as RAGE presence on circulating cells with increased AGE levels in the blood [127-129] 
and underscores the importance of RAGE as a propagator of cellular dysfunction. 
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The RAGE receptor has a molecular weight of 35 kDa, and it is made up of three 
extracellular domains, with the V-type acting as the principal domain for ligand binding 
[223]. It also has a transmembrane and an intracellular domain that transmit signals 
intracellularly for a RAGE-mediated response to occur [224]. Upregulation of RAGE on 
the cell surface is regulated by nuclear factor kappa B (NF-kB), interferon-γ response 
element and IL-6 DNA factor, which all have sites on the RAGE promoter [225].  
In EC, SMC and monocytes, RAGE-AGE binding can cause cellular activation 
leading to ras21 and MAPK signaling cascade activation [130, 226]. There is also an 
increase in oxidative stress in endothelial cells as a result of RAGE/AGE signaling due to 
an increase in NADPH oxidase, which then leads to the activation of many other signaling 
pathways [227]. With MAPK and oxidative stress signaling, the NF-kB transcription factor 
is activated, which further leads to an increase in the upregulation of adhesion molecules 
on the EC and monocyte. These include ICAM-1, VCAM-1 and E-selectin. This increase 
in adhesion molecule expression increases the adhesion of monocytes to EC and ECM 
[131, 147]. In addition, there is high proinflammatory cytokine production (TNF-α, IL-1 
and 6, MCP-1) which further causes more RAGE upregulation on the cell surface [131, 
225, 228]. MCP-1 was the first cytokine to be discovered because it is highly abundant and 
plays the role of attracting monocytes/macrophages to sites of vascular 
growth/inflammation. It aids the migration of monocytes/macrophages into the vessel wall. 
Different cell types such as EC, SMC, monocytes, epithelial cells and fibroblasts also 
produce it. TNF-α also acts to further promote the chemoattractant action of MCP-1 [229]  
Continuous signaling through RAGE/AGE produces an increased activation of 
MAPKs and GTPases, key factors for the needed migratory response of 
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angiogenic/arteriogenic cells during new blood vessel growth. Therefore, along with the 
increase in monocyte cellular adhesiveness in diabetes and hyperglycemia, monocytes lose 
their natural ability to migrate towards the normal gradient of angiogenic/arteriogenic 
growth factor stimuli created, for example, by VEGF [139] and PLGF [230]. 
Negative coronary artery remodeling in diabetes has been associated with an 
increase in glycated blood protein (albumin) and a decrease in the soluble RAGE receptor 
in diabetic patients [231]. 
Endothelial cells in diabetic patients have been shown to be constantly exposed to 
circulating AGE. Nitric oxide, a substance that promotes vasodilation, has been shown to 
be reduced in the vessel wall of patients with type 2 diabetes due to elevated production of 
superoxide caused by an interaction of RAGE/AGE and TNF-α signaling. In this 
experiment, RAGE was upregulated in diabetic coronary arterioles and as a result 
augmented the expression of TNF-α. To prove this, sRAGE and NF-kB inhibitor, was used 
to attenuate the increase in TNFα and RAGE [232]. 
Diabetes-associated accumulation of AGE is thought to induce overproduction of 
TNF-α from macrophages. This effect has been implicated in reduced vascular growth 
[233]. 
Monocytes 
The blood, the medium of nutrient transport to all parts of the body, has three 
specialized cellular elements (erythrocytes, leukocytes and platelets), all suspended in the 
liquid part, also called plasma. Monocytes are one of the five types of leukocytes (white 
blood cells) found in the blood and represent about 2-10% of leukocytes. The others are 
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neutrophils, eosinophils, basophils and lymphocytes. Monocytes and lymphocytes are 
known as mononuclear agranulocytes because they have one nucleus but lack membrane-
enclosed granules in their cytoplasm. The monocyte is the larger of the two, with a kidney 
shaped nucleus, while lymphocytes have a spherical shaped nucleus and are the smallest 
of all five leukocyte types. The other three are termed polymorphonuclear granulocytes. 
They have many-lobed nuclei and contain granules [4]. 
Monocytes are migratory because they can leave the blood under certain 
pathological conditions and during inflammation and move into surrounding tissues. They 
can divide and when stimulated, can differentiate into macrophages (macro=large; 
phages=eater). The reaction that occurs between the blood and the surrounding tissues in 
response to injury is called inflammation. It results in redness of the site, pallor, swelling 
and hotness (heat). The macrophages work as phagocytes, ingesting foreign materials, 
bacteria, and also work in tissue repair [234]. They are involved in both innate immunity 
and also influence the process of adaptive immunity. They have multiple roles in immune 
function, including: acting as tissue resident macrophages in normal conditions (ready to 
phagocytize any incoming foreign object), migrating to sites of resolution or injury within 
approximately 8-12 hours in response to signals of inflammation, and differentiating into 
macrophages or dendritic cells in order to cause an immune response. Half of the 
monocytes produced are stored in the spleen [235]. They can then transform into 
macrophages after penetrating the appropriate tissues. They can also transform into foam 
cells in the endothelium especially after ingesting lipids.  
There are three classes of monocytes in human blood which are classified based on 
the type of receptor they upregulate on their cell surface [236]. The first is known as 
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classical monocytes. They have a high expression of CD14 cell surface receptor (CD14++ 
CD16-). The second is known as the non-classical monocyte. It expresses a low level of 
the CD14 receptor but has an additional co-expression of the CD16 cell surface receptor 
(CD14+ CD16++). The third class is the intermediate monocyte with high level of CD14 
and low level of CD16 receptor expression (CD14++ CD16+) [237]. The level of CD14 cell 
surface receptor on a macrophage can be used to differentiate between the different classes 
of monocyte, especially between the non-classical and intermediate. Studies show that the 
intermediate monocytes is a unique class of monocytes because of their high expression of 
surface receptors which are involved in reparative processes, especially VEGFR-1 and 2 
and because they are produced abundantly by the bone marrow [238]. They also produce 
an increased amount of proinflammatory cytokines like TNF-α and IL-12 after stimulation 
with microbial agents.  
In mice, monocytes have two classes. Inflammatory monocytes (Cx3CR1low, 
CCR2+, Ly6Chigh). This class compares with the human classical CD14++ CD16- class of 
monocytes. Second in mice is the resident monocytes (Cx3CR1high, CCR2neg, Ly6Clow) that 
compares to the human non-classical CD14low CD16+ monocytes. Resident macrophages 
in mice roam around the endothelial cell wall both in physiological and inflammatory state 
[239-241]. The classical and non-classical monocytes in man crawl and do not roam along 
the endothelial wall [242]. 
Monocytes are the largest of the leukocytes [243] and are produced in the bone 
marrow and circulate in the blood for 1-3 days before moving into tissues in different parts 
of the body where they differentiate into macrophage and dendritic cells. Monocytes can 
be made to differentiate into dendritic cells in vitro by adding the GM-CSF cytokine and 
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IL-4 [244]. Therefore, overall monocytes are involved in phagocytosis, antigen 
presentation to T cells, and cytokine production. 
Substances produced by other cell types can influence the chemotactic behavior 
and other functions of monocytes. These include chemokines such as monocyte 
chemotactic protein-1 (MCP-1 or CCL2) and monocyte chemotactic protein-3 (MCP-3 or 
CCL7) and some arachidonic acid metabolites, like N-formyl methionine leucyl-
phenylalanine which is made by bacteria and can activate the formyl peptide receptor 1 on 
the monocytes [245]. Some microbial products can even directly activate monocytes. This 
gives rise first to production of pro-inflammatory cytokines and later, anti-inflammatory 
cytokine production. Cytokines produced by monocytes include TNF-α, IL-1 and IL-12. 
It is important to note that the monocyte count, expressed as a percentage of 
monocytes relative to other leukocytes, can be used to express a prevailing situation or 
disease. Monocytosis is when there is the presence of an excess amount of monocytes. It 
gives an indication of certain disease states such as chronic inflammation, atherosclerosis, 
necrosis, and immune-mediated disease [246]. For instance, a high count of 
CD14+CD16++ monocytes may indicate sepsis [247] while a high count of CD14++ 
CD16+ intermediate monocytes is a predictor of cardiovascular disease in high risk 
populations [248, 249]. 
Monocytopenia occurs when there is a decrease or deficiency of monocytes. This 
is usually the case after treatment with glucocorticoids (immune-suppressive agents) [250]. 
Adherence of monocytes to the vessel wall and differentiation into macrophages is 
a very important event in collateral growth. Monocytes produce a host of cytokines, growth 
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factors and proteases (to break down ECM) needed in collateral growth [65, 251]. 
Monocyte infiltration into growing collaterals has been observed as early as day 3 after 
occlusion in an experiment of hindlimb ischemia that revealed abundantly growing 
collaterals [251]. Others also have reported that an increase in migration of blood 
monocytes increases collateral growth, and that a reduction in the number of infiltrating 
monocytes reduces arteriogenesis. In that study, when an exogenous infusion of monocytes 
was given, arteriogenesis was improved, demonstrating the importance of migrating 
monocytes in arteriogenesis [252]. 
PLGF is a key growth factor produced during the early stages of arteriogenesis. It 
acts as a chemoattractant for monocytes and interacts with the VEGFR-1 receptor on the 
monocytes [177, 253]. Similarly, activated EC produce MCP-1 in response to shear stress 
which activates the MCP-1 receptor, chemokine receptor 2 (CCR-2). In response to these 
signals, monocytes infiltrate the vessel wall and produce additional factors that stimulate 
arteriogenesis. For example, monocytes produce TNF-α and bFGF at sites of collateral 
growth [254]. TNF-α was shown to contribute to arteriogenesis in a study where LPS (a 
known inducer of TNF-α) was administered. TNF-α further promotes the monocyte 
response by causing an upregulation of adhesion molecules on both endothelial cells and 
monocytes. TNF-α and bFGF are mitogenic for EC and SMC and bFGF also potentiates 
the effect of VEGF [63]. The binding of CCR- 2 to MCP-1 also stimulates the monocytes 
to produce MMPs that break down the extracellular matrix as they progress into the wall 
to create space for expansion of the vessel.  
In an experiment to illustrate the importance of monocyte migration, New Zealand 
white diabetic rabbits were subjected to femoral artery ligation. They developed collateral 
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arteries with a narrow diameter, which had reduced blood flow compared to collaterals in 
control rabbits. When monocytes from these animals were checked for VEGF-A and MCP-
1 mediated chemotaxis, the response of the diabetic monocytes was significantly reduced 
compared to the non-diabetic monocytes. This was a very specific reduction, as the 
monocytes only failed to respond to VEGF-A and MCP-1 but responded to other 
chemoattractant such as FormylMetLeuPhe (fMLP) [255].  
In another experiment, cell transplantation was used to enhance homing of 
macrophages to an area of collateral growth, yielding a strong arteriogenic response. This 
result suggests that targeting the innate and adaptive immune response might be an 
effective way to clinically boost collateralization. Similarly, another study systemically 
transplanted human macrophages into a mouse model of hindlimb ischemia. Collateral 
growth was strongly increased, as shown by more collateral arteries within the adductor 
muscles and better clinical scores. There was also a significant reduction in TNF-α, IFN-
γ, IL-4, IL-5, IL-6, and IL-10 8 h after the systemic monocyte transplantation. These 
authors speculated that treatment with one growth factor produced by macrophages cannot 
be as effective at improving arteriogenesis, but that monocyte transplantation would allow 
the monocytes to locally secrete all of the necessary growth factors and cytokines in the 
correct amount and at the appropriate time, and to communicate with other cells involved 







Inflammation is a local response of a tissue to damage or infection that has a strong 
vascular component. In inflammation, there is an increase in the blood supply to the 
affected area. The endothelial cells shrink, causing an increase in capillary fluid filtration 
and allowing cells from the blood to extrasavate into the tissues. Leukocytes, monocytes, 
and lymphocytes crawl out of the bloodstream to participate in the inflammatory response 
and resolve the injury. The cytokines produced by these infiltrating cells and by the 
endothelial cells can penetrate the tissues as well.  
Cytokines are small proteins that act in an autocrine (acting on cells that produce 
them) or paracrine (acting on neighboring cells) manner. They produce their action at a 
short distance around where they are secreted rather than at a distance (no endocrine 
action). They are very potent, and induce their action even at picomolar or femtomolar 
levels. In it all, their production is usually transient and tightly regulated. Examples include 
interferons, interleukins, colony stimulating factors and chemokines (which have 
chemoattractant properties and direct the movement of cells during migration from 
bloodstream into inflammatory tissues [94] Generally, cytokines are classified into two 
categories. First are the pro-inflammatory cytokines which include interleukin-1 (IL-1), 
tumor necrosis factor (TNFα), interferon gamma (IFN-γ), IL-6, IL-12, IL-18, and 
granulocyte-macrophage colony stimulating factor (GM-CSF), a chemokine [257]. The 
second group are the anti-inflammatory cytokines, which include IL-4, IL-10, IL-13, IFN-
α, and transforming growth factor-β (TGF-β) [258]. The interplay between these two 
groups determines what type of inflammation would occur at a given site of action. An 
imbalance of one group over the other drives certain pathological states.  
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Adaptive collateral vessel growth (arteriogenesis) is an inflammatory process that 
involves the production and release of pro-inflammatory cytokines, infiltration of 
monocytes into the tissues and production of growth factors that trigger the growth and 
expansion of small existing collaterals [259]. Shear stress is the triggering force that 
initiates arteriogenesis, and is closely followed by the migration of inflammatory cells. 
Inflammatory cell infiltration is critical for arteriogenesis, since a reduction in the number 
of infiltrating cells, a blockage of their adhesion [260] to endothelial cells, or prevention of 
their migration attenuates arteriogenesis [261]. Infiltrating bone marrow derived 
macrophages have been shown to be a major determinant of growth factor production. In 
a mouse hindlimb ischemia model, bone marrow transplantation from PLGF knockout 
mice to wild type mice led to a significant reduction in blood vessel growth [262]. In 
collateral growth, monocytes/macrophages release inflammatory cytokines such as TNF-
α, IL-1 and IFN-γ. These cytokines cause endothelial adhesion molecules like ICAM-1 and 
VCAM-1 to be upregulated at sites of inflammation. Signaling through pathogen 
associated molecular pattern receptors (PAMPs) and Toll-Like Receptors (TLRs, 
especially TLR-2 and TLR-4) expressed by macrophages has also been implicated in 
arteriogenesis in some studies [69, 263-265]. 
Advanced glycation end products (AGE) and inflammation 
As discussed in earlier sections, AGE (products formed from irreversible non–
enzymatic glycation of proteins, lipids and nucleic acid), are toxic substances found in the 
plasma which are implicated in diabetes and cardiovascular diseases. AGE are also 
associated with inflammation and oxidative stress [266, 267]. AGE have been proven to be 
antigenic and to induce an immune response in the body [268, 269]. AGE can interact with 
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two types of receptors: macrophage receptors and the receptor for AGE (RAGE) [270]. 
Macrophage scavenger receptors (mentioned above) are responsible for AGE capture, 
removal, and breakdown. Recently, studies have shown that AGE can also signal through 
receptors found on the surface of macrophages. Examples include the TLRs and CD14 
[271]. RAGE is expressed on endothelial cells, on the surface of macrophages, and in 
various tissues including heart and skeletal muscle. Activation of RAGE stimulates a 
specific signaling pathway in response to AGE binding. In macrophages, AGE has been 
shown to cause elevated production of IL-1β and TNF-β via RAGE signaling [272].  
Many studies have linked AGE to the endothelial dysfunction observed in diabetes, 
by causing overproduction of proinflammatory cytokines in macrophages, leading to 
macrophage malfunction and death [273, 274]. Glycated albumin, one type of AGE, 
stimulates excessive production of IL-8, IL-6 and TNF-α [275]. In fact, regression analysis 
shows that the glycated albumin concentration is correlated with the level of TNF-α and 
the glucose concentration in the blood of diabetic patients [276]. Interestingly, some 
researchers have suggested that AGE affects TNF-α production and TNF-α in turn, affects 
AGE levels [275, 276]. Therefore, given the strong relationship between AGE, 
inflammatory signaling, and diabetic complications, concerted efforts have been made to 
develop agents that would break down AGE or reduce the damage caused by AGE. 
Amongst these initiatives are the use of AGE inhibitors and breakers (aminoguanidine, 
alagebrium, statins, antioxidants, natural phenolic substances) and also the use of anti-
inflammatory molecules [277-280]. Anti-inflammatory drugs and AGE inhibitors that act 
on activated macrophages have been used to suppress AGE induced overexpression of 
cytokines [281, 282]. Studies have shown that inhibitors of AGE have anti-inflammatory 
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actions, and can deactivate macrophages and reduce excessive production of cytokines that 
cause tissue damage. Interestingly, these studies also show that macrophages themselves 
can secrete AGE and that blocking the production of AGE in macrophages can reduce AGE 
levels and excessive cytokine production [283]. In summary, AGE is involved in the 
production of pro-inflammatory mediators, which in turn is implicated in the pathogenesis 
of diabetes-associated cardiovascular disease. 
From this literature review, it has been established that arteriogenesis is reduced 
in coronary and peripheral arteries by diabetes, but that the mechanism by which this 
occurs is not well defined. Therefore, the key questions that our lab seeks to answer are: 
1) how does diabetes inhibit arteriogenesis? and 2) what are the signaling pathways 
involved? Since PLGF is the key arteriogenic growth factor involved in monocyte 
recruitment and collateral growth, our group is currently working to determine how 
diabetes affect its expression as a step towards answering these key questions. 
Previous results from our lab indicated that PLGF is highly expressed by 
endothelial cells, and is also found in skeletal muscle and cardiac myocytes. Critically, 
we found that the PLGF protein level in skeletal and cardiac muscle was reduced in mice 
fed a Western diet. This reduction was apparent both at the basal (unstimulated) level, 
and in the response to femoral artery ligation (a physiological stimulus for 
arteriogenesis). Therefore, it seems likely that reduced PLGF expression could play a key 
role in the inhibition of arteriogenesis, which has been observed in diabetes. 
To investigate the mechanism for this reduction, our group previously conducted 
in vitro treatment studies of endothelial and skeletal muscle cells in which we attempted 
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to isolate the effect of various metabolic factors involved in the diabetic phenotype by 
exposing cells to cholesterol, glucose, insulin, and oxidative stress. Since PLGF levels 
were not affected by any of these factors, we were led to consider what additional factors 
found in vivo could be tested. In our prior in vivo study, advanced glycation end product 
(AGE) levels were elevated in hindlimb skeletal muscle. As described in this review, 
there is an established connection between AGE and vascular dysfunction in diabetes. 
Therefore, the overall goal of the present study was to test the hypothesis that AGE 
inhibits PLGF expression in endothelial and skeletal muscle cells. 
Previous results in our lab also revealed that PLGF levels in human coronary 
endothelial cells were decreased by treatment with recombinant tumor necrosis factor 
alpha (TNFα). AGE is known to induce TNFα expression, as discussed in this review; 
therefore, we further hypothesized that AGE would exert its effects on PLGF through 
TNFα. 
In the present study, we tested this hypothesis by examining both the direct and 
indirect effects of AGE on PLGF expression in HCAEC and SKMC. We also 
investigated the potential role of macrophages in this signaling pathway, as well as the 
influence of endothelial cell activation state on responsiveness to AGE. These studies 
have generated new insights into a potential mechanism contributing to the diabetes-
induced impairment of arteriogenesis and may lead to future therapies aimed at 







MATERIALS AND METHOD 
 
 
Human Primary Cells  
 
Human coronary endothelial cells (HCAEC) and human skeletal muscle cells 
(HSKMC) were purchased from Lonza. Cells were grown in either endothelial cell 
growth medium (EGM-2MV) or skeletal muscle cell growth medium (SKGM), 
respectively, supplemented with growth factors (Lonza). Cells were grown to confluence 
at 370C in a humidified incubator containing 5% CO2. Culture medium was changed the 
day after cells were subcultured and refreshed every other day thereafter. For 
experiments, equal numbers of cells were seeded into each well of 6- or 12-well plates. 
HCAECs were used at passage 4 and HSKMC were used at passage 5.   
Established Cell Lines 
Mouse hemangioendothelioma endothelial cells (EOMA) was purchased from 
American Type Culture Collection (ATCC). Cell were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM/High Glucose, Invitrogen), containing L-glutamine, and 
supplemented with 5% fetal bovine serum and 1% penicillin/streptomycin. Mouse 
skeletal muscle cells (C2C12) and RAW 264.7 murine macrophages were provided by 
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Drs. Stephen Clarke and Ranjan (OSU) respectively and were grown in DMEM 
supplemented with 5% and 10% fetal bovine serum and 1% penicillin/streptomycin 
respectively. Cells were grown to confluence at 370C in a humidified incubator 
containing 5% CO2. Culture medium was changed the day after cells were subcultured 
and refreshed every other day (for the C2C12) and every three days (for the RAW 264.7 
cells) thereafter. For experiments, RAW 264.7 cells were used at passage 10 and 
MSKMCs were used at passage 8. EOMA cells were at passage 7. 
Advanced Glycation End Products (AGE) Preparation 
 
 AGE was prepared through the non-enzymatic glycation of bovine serum albumin 
(BSA) in the presence of D-(+) glucose or DL-glyceraldehyde. Briefly, a 50mg/ml or 
25mg/mL solution of BSA (Sigma-Aldrich, St. Louis, MO) for glucose or glyceraldehyde 
derived AGE respectively,  was incubated in the presence of 45mg/ml D-glucose or 20 
mM DL-glyceraldehyde (Sigma-Aldrich) in phosphate buffered saline (PBS, pH 7.4). 
The solution temperature was maintained at 37˚C for 8weeks or 1 wk. respectively, to 
fully glycate the albumin and to prepare irreversibly formed AGE. As a control, 50mg/ml 
or 25 mg/mL BSA (for glucose or glyceraldehyde controls respectively) was also 
incubated in PBS in the absence of DL-glyceraldehyde for 8weeks or 1 wk. at 37˚C. 
After the incubation period, both the control, glucose and glyceraldehyde-glycated 
samples were dialyzed in fresh PBS at 4˚C every 2 h for a total of 4 changes. The glucose 
or glyceraldehyde derived AGE was centrifuged at 3,000 rpm for 30 min in Amicon 
concentrator tubes (Millipore, Billerica, MA) to concentrate the AGE solution. Total 
protein concentration in the control and AGE preparations was quantified using the BCA 
assay (Pierce, Rockford, IL). BSA and AGE samples were determined to be endotoxin 
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free by testing with the LAL chromogenic Endotoxin Quantitation Kit (Life Technologies 
Corporation, Grand Island, NY). Endotoxin values were less than 1.0EU/mL. The AGE 
level in the BSA and AGE solutions was measured by ELISA (OxiSelect Advanced 
Glycation End Product Competitive ELISA kit, Cell Biolabs). 
Treatment of Cells 
 
AGE treatment. Confluent HCAECs, HSKMCs, MSKMCs, and RAW 264.7 cells 
were treated with either BSA or AGE at 1000-1500 µg/mL for 24 h. Untreated cells 
served as a control group.  
Growth factor treatment. In some experiments, HCAECs and HSKMCs were 
treated with recombinant TNFα protein (R&D Systems) at concentrations ranging from 0 
ng/mL to 100ng/mL for 24 h. In other studies, cells were treated with recombinant IL-1 
protein at concentrations ranging from of 0 pg/mL-100,000pg/mL. 
RAW-conditioned media treatment. For experiments on RAW-conditioned 
media, RAW cells were treated as described above. Media was then collected and 
centrifuged at 1500x g for 10 min to pellet any cells. The RAW media was then added to 
confluent EOMA cells and incubated at 37oC for 24 h.  
Endothelial cell activation. For studies of endothelial cell activation, HCAECs 
were pre-incubated with BSA or AGE at 1000μg/ml at the moment of subcultuing of 
cells into the 6 or 12- well plates and when confluent, was treated with a combination of 
inflammatory mediators: IL-1 (ThermoFisher) at 1 ng/mL, LPS (InvivoGen) at 2 µg/mL, 
and IFN-γ (PeproTech) at 20 ng/mL and further incubated for 24 h. 
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Macrophage activation. For studies on macrophage cell activation, confluent 
RAW 264.7 cells were treated with two concentration of LPS (InvivoGen) at 50ng/ml 
and 500ng/ml. 
All treatments were added directly to the cell medium. Samples of culture 
medium were collected 24 or 48 h post-treatment into fresh tubes containing protease 
inhibitors for measurement of PLGF and TNFα protein levels.  
Enzyme-Linked Immunosorbent Assay (ELISA) 
 
Mouse and human PLGF and TNFα protein concentrations were quantified in the 
media samples by ELISA (Mouse and Human DuoSet ELISAs, R&D Systems) following 
the manufacturer’s protocols. All samples were assayed in duplicate. The assay plates 
were read using a BioTek Synergy HT plate reader (BioTek Instruments) at 450 nm. All 
data were normalized to total protein concentration in the samples, using the 
bicinchoninic acid assay (BCA, Pierce), except in experiments where BSA and AGE 




The reverse transcription-polymerase chain reaction (RT-PCR) technique was 
employed to quantify the mRNA expression of mouse and human PLGF, TNFα, VCAM-
1, ICAM-1, MCP-1, RAGE, and β-actin in HCAEC, HSKMC, RAW 264.7, and EOMA. 
Total RNA was collected using the RNeasy mini kit (Qiagen) following the manufacturer 
provided protocol. The quantity and purity of total RNA was analyzed by the A260/280 
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ratio using a Take3 micro volume plate on the BioTek Synergy HT Multi-mode Plate 
Reader (BioTek Instruments). RNA samples were either directly used for PCR or stored 
at -80°C until use. RNA was reverse transcribed to cDNA using the QuantiTect reverse 
transcription kit (Qiagen) according to the manufacturer’s instructions. Target genes were 
amplified from cDNA in an ABI 7500 Fast instrument (Life Technologies, Grand Island, 
NY) using PerfeCTa SYBR Green FastMix, Low ROX (Quanta Biosciences) with the 
appropriate forward and reverse primers. Forward and reverse primers were used as 
shown in the table below. The relative PLGF, TNFα, MCP-1, RAGE, VCAM-1, and 
ICAM-1 mRNA expression (RQ value) was quantified using the comparative ∆∆Ct 
method. Target gene expression was normalized to β-actin gene expression. 
Mouse Multiplex Cytokine Assay 
 
  Cytokines secreted by the RAW 264.7 cells into the media were analyzed using a 
multiplex Pro Mouse Cytokine 6-Plex panel and cytokine reagent kit (Bio-Rad), 
following the manufacturer’s protocol. A Luminex-100 instrument with Bio-Plex 
Manager 6.1 software (Bio-Rad Laboratories) was used.  
Statistical Analysis 
 
All data are presented as mean ± SEM. The GraphPad Prism statistical package 
was used for data analysis. One way analysis of variance (ANOVA) followed by post-hoc test 




List of Primers 
 
Mouse PLGF Forward CTGCTGGGAACAACTCAACAGA 
  Reverse GCGACCCCACACTTCGTT 
Mouse TNFα Forward GACGTGGAACTGGCAGAAGA 
  Reverse GAGGCTGAGACATAGGCACC 
Mouse VCAM-1 Forward TGAAGATGGTCGCGGTCTTG 
  Reverse AGCTTGAGAGACTGCAAACAG 
Mouse ICAM-1 Forward TCCGCTGTGCTTTGAGAACT 
  Reverse TCCGGAAACGAATACACGGT 
Mouse MCP-1 Forward GGCTCAGCCAGATGCAGTTAA 
  Reverse CCTACTCATTGGGATCATCTTGCT 
Mouse RAGE Forward CAAGGAGGAACCACCCATCC 
  Reverse CAACCAACAGCTGAATGCCC 
Mouse Β-actin Forward AGTTCGCCATGGATGACGAT 
  Reverse TGCCGGAGCCGTTGTC 
Human PLGF Forward CCTACGTGGAGCTGACGTTCT 
  Reverse TCCTTTCCGGCTTCA TCTTCT 
Human TNFα Forward GAATCGGATCAGGGAGGATG 
  Reverse AAGTTGGGGACACACAAGCA 
Human VCAM-1 Forward ATGTCAATGTTGCCCCCAGA 
  Reverse TGCTCCACAGGATTTTCGGA  
Human ICAM-1 Forward CCATCTACAGCTTTCCGGCG 
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  Reverse TCAGCGTCACCTTGGCTCTA 
Human MCP-1 Forward TGCTCATAGCAGCCACCTTC 
  Reverse GGGCATTGATTGCATCTGGC 
Human RAGE Forward ATTGGTGGTGGAGCCAGAAG 
  Reverse CAGGTCAGGGTTACGGTTCC 
Human Β-actin Forward TGCCGACAGGATGCAGAAG 










AGE had no direct effect on PLGF expression 
 
To test the effect of AGE on PLGF expression, confluent cell cultures of HCAEC, 
HSKMC and MSKMC were treated with BSA or AGE at 1000μg/ml for 24 hours. 
Treatment with AGE or BSA had no significant effect on PLGF protein levels in media 
in HCEAC and HSKMC (Fig 4). This lack of direct effect of AGE was also observed in 
PLGF mRNA (Fig. 5). However, there was a slight but significant direct effect of AGE 
on PLGF in MSKMC (Fig. 6). 
Recombinant TNFα reduced PLGF protein levels in HCAEC but had no effect on 
HSKMC and MSKMC 
 
We next sought to see if AGE could possibly indirectly affect PLGF protein 
levels in HCAEC, HSKMC and MSKMC via a mediator such as TNFα. As a first step in 
testing this hypothesis, HCAEC, HSKMC and MSKMC were treated with recombinant 
TNFα protein. There was a significant reduction in PLGF protein levels at TNFα 
concentrations between 0.1ng/ml-50ng/ml (Fig. 7 P=0.0001). TNFα had no significant 
effect on HSKMC and MSKMC (Fig. 8). 
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Recombinant IL-1 Treatment had no significant effect on PLGF protein levels in 
HCAEC 
 
IL-1 is another mediator we tested on HCAEC, to show its effect on PLGF. IL-1 
had no significant effect on HCAEC (Fig.9) 
Direct Effect of AGE on TNFα stimulation in EC and SKMCs 
 
We next tested whether direct treatment with AGE could increase TNFα levels in 
HCAEC or HSKMC. Confluent HCAEC and HSKMC were treated directly with AGE or 
BSA at 1000-1500μg/ml. TNFα protein levels were measured. TNFα was undetectable in 
the cells across all treatments. Therefore, we concluded that AGE had no direct effect on 
TNFα production in EC (data not shown). 
AGE increased TNFα protein levels in murine macrophages 
 
To further explore our hypothesis that AGE could be having indirect effects on 
EC, we next characterized the effect of AGE on TNFα expression in macrophages. RAW 
264.7 murine macrophages were treated with AGE or BSA at 1000 or 1500μg/ml. TNFα 
was significantly increased in AGE treated RAW cells as compared to BSA-treated or 
untreated control cells (Fig. 10  P<0.0001). 
We also quantified the PLGF protein level in the RAW 264.7 macrophages to see 
whether macrophages themselves make PLGF protein when activated by AGE. PLGF 





AGE-treated macrophage media increased TNFα production in endothelial cells 
while AGE and BSA-treated macrophage media both reduced PLGF in EC 
 
Because we have seen that PLGF levels was reduced by treatment with 
recombinant TNFα and that AGE stimulated the production of TNFα in macrophages, we 
sought to determine the effect of conditioned media from macrophages (media from the 
BSA or AGE treated RAW 264.7 cells), on PLGF expression in EC. To do this, we 
cultured EOMA cells (murine ECs) and incubated them with BSA and AGE treated 
RAW cell conditioned media that had been centrifuged (to ensure that just the media was 
added to EOMA cells).  
TNFα protein was significantly increased in EOMA cells incubated with AGE-
treated RAW media, but not in cells incubated with BSA-treated and untreated (control) 
RAW media (Fig. 11 P< 0.0001). However, TNFα mRNA was not significantly different 
across the three treatments (Fig. 12). 
Excitingly, PLGF was significantly reduced in EC incubated with AGE-treated 
RAW media; unexpectedly, PLGF was also significantly reduced in EC exposed to BSA-
treated RAW media (Fig. 13 P<0.001). 
Endothelial cells pre-incubated with AGE and activated with inflammatory 
mediators increased TNFα expression   
 
EOMA ECs were pre-incubated with BSA or AGE at 1000μg/ml and when cells 
were confluent, they were activated and treated with a combination of three inflammatory 
mediators (IL-1, LPS and IFN-γ; ILI). TNFα expression was increased in the AGE 
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treated cells, in comparison with the BSA or untreated control cells (Fig. 14 P<0.001). 
There was no significant difference in TNFα mRNA (Fig. 12).  
TNFα was the most abundantly produced cytokine by AGE activated RAW 
macrophages, followed by IL-10 and IFN-γ 
 
Macrophage media treated with BSA or AGE was further analyzed using a 6-
panel multiplex mouse cytokine assay, to check for other cytokines that may be produced 
by the RAW cells in response to AGE or BSA. TNFα was the most significantly 
increased of all the cytokines quantified (P=0.007). There was also a trend towards an 
increase in IL-10 and IFN-γ with AGE treatment (Fig. 15 P=0.06). 
Stimulation of murine EC (EOMA) with LPS further decreased PLGF.  
 
Confluent EOMA cells were directly treated with LPS at 0, 50, and 500ng/ml to 
see the effect of LPS on PLGF levels. LPS is a known stimulator of TNFα, and since LPS 
was amongst the previous three inflammatory cytokines that caused overexpression of 
TNFα, it was used to treat EOMA cells directly without incubation with AGE. The 
results showed a significant decrease in PLGF. This is consistent with a TNFα-mediated 
effect on PLGF regulation (Fig. 14B) 
Direct AGE treatment of HCAEC had no significant effect of ICAM-1, VCAM-1, 
TNFα, MCP-1 and RAGE mRNA.  
 
Following AGE treatment, there was no significant change in the mRNA levels of 
adhesion molecules that would normally be upregulated when there is EC activation. 
Intracellular adhesion molecule (ICAM-1), vascular cell adhesion molecule (VCAM-1) 
macrophage chemoattractant molecule (MCP-1), and tumor necrosis factor (TNF-α) 
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mRNA levels were not significantly affected by direct treatment of AGE in HCAEC. 
RAGE mRNA, on the other hand, tended towards an increase which may become 
significant with increase in sample size. RAGE is the receptor for AGE which is found on 
many cell types (Fig 16) 
TNFα mRNA was not significantly affected in RAW-AGE treated media and RAGE 
is downregulated in activated RAW media 
 
RAW 264.7 cells were stimulated with AGE or BSA at 1000μg/ml for 24 hours. 
TNFα mRNA was not significantly increased in the RAW cells, despite the increased 
expression of TNFα protein. Interestingly, mRNA for RAGE, the receptor for AGE, is 
downregulated in the RAW cells (Fig 17). This finding suggests that AGE may not be 
signaling through RAGE on macrophages, since there are other receptors also present on 
the macrophage cell surface like TLRs and macrophage scavenger receptors. 
MCP-1, RAGE and TNFα were insignificant in EOMA cell incubated with AGE-
treated RAW media 
 
After incubation of EOMA cells with AGE or BSA treated RAW media, the 
mRNA levels of MCP-1, RAGE, TNFα and PLGF were measured. There was no 
significant change observed in the mRNAs measured in the AGE-RAW media incubated 
EOMA cells when compared with the BSA-treated RAW media incubated EOMA. TNFα 
mRNA tended towards an increase, but was insignificant when compared between the 
two treatments (Fig. 18) 
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From these results, we see that AGE had no direct effect on PLGF regulation, but 
that AGE treated macrophage media caused a very significant change in the effect of 






Figure 4. AGE had no direct effect on HCAEC. PLGF protein level was measured at different 
time points using ELISA. There is no statistical difference between the BSA-control treated and 



























Figure 5 AGE had no direct effect on PLGF mRNA in HCAEC. PLGF mRNA was not 
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Figure 6. AGE had no direct effect on HSKMC but had an effect on MSKMC. A) PLGF protein 
levels was not significant between the AGE-treated and the BSA-treated cells in HSKMC (N=6, 
P=NS) but in B) there was a significant decrease in PLGF in MSKMC glucose-AGE-treated cells 
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Figure 7. Recombinant TNFα decreased PLGF levels in HCAEC. Direct treatment of confluent 
HCAEC with recombinant TNFα between 0ng/ml-50ng/ml concentrations significantly reduced 




























Figure 8. Recombinant TNFα treatment in HSKMC and MSKMC. A) Recombinant TNFα had no 















































Figure 9. IL-1 had no significant effect on PLGF in HCAEC. Treatment of confluent HCAEC 
cells with other inflammatory markers such as IL-1 showed no consistent effect on regulation of 




















Figure 10.  AGE increased expression of TNFα in macrophages. AGE-treated cells showed 
overexpression of TNFα production in RAW 264.7 murine macrophage cells in comparison to 
BSA or untreated control cells. A) At 1000μg/ml and at B) 1500μg/ml of BSA or AGE 
concentration for 24 hours. N=4, P=0.0001. PLGF protein levels were undetectable in RAW 









































Figure 11.  RAW media treated with AGE significantly increased TNFα protein levels in EOMA 
cell media than in BSA-treated or untreated control-RAW media incubated EOMA cells. RAW 
media stimulated with BSA or AGE was collected, centrifuged, added to growing EOMA cells in 
































TNFα conc in EOMA cells incubated with 
RAW Media treated BSA/AGE at 1500μg/ml 
for 24hrs *
B 
TNFα conc in EOMA cells incubated with RAW 
media treated BSA/AGE at 1000μg/ml for 24hrs 
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wells incubated with 1000μg/ml and B) 1500μg/ml AGE-treated RAW media than in the BSA or 




Figure 12.  TNFα mRNA was not significantly different between EOMA cells incubated with 
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Fig 13. RAW media treated with BSA or AGE decreased PLGF levels in EOMA EC. A) at 
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reduced in the AGE-treated RAW media incubated EOMA EC and in the BSA- control, RAW 









Fig 13 C. RAW media treated with BSA or AGE decreased PLGF levels in EOMA EC. C) in 
RAW media treated with 1000μg/ml BSA or AGE for 4 hours and then added to EOMA EC and 
incubated for 18hours, PLGF was also reduced in the AGE-treated RAW media incubated EOMA 
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Fig 14. TNFα is overexpressed in HCAEC pre-incubated with AGE and activated by treatment 
with inflammatory markers. HCAEC were pre-incubated with AGE or BSA at 1000μg/ml for 
24hours and then activated with a combination of inflammatory markers, IL-1 1ng/ml, LPS 
2μg/ml and IFN-γ 20ng/ml (ILF). A) AGE pre-incubation caused an increased expression of 
TNFα in the HCAEC than BSA or untreated control pre-incubated ECs. N=4, P=0.001. B) LPS 
also reduced PLGF levels when used to treat RAW 264.7 cells for 4 hours and incubated on 
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Fig 15. TNFα is the 
cytokine most 
secreted by RAW 
264.7 murine 
macrophages. Further 
testing to confirm 
other cytokines 
secreted by RAW 
macrophages into the 
media, that may be 
having an effect on 
PLGF regulation was 
carried out using a 
multiplex mouse 
cytokine assay. A) 
TNFα was most 
significantly 
increased in the media 
of AGE treated RAW 
cells compared to 
BSA treated or 
untreated-control 
RAW cell media N=6, 
P=0.007. There was a 
trend towards increase 
in B) IL-10, N=6, 








Fig 16. AGE did not directly activate endothelial cells. mRNA gene expression of adhesion 
molecules, cell surface receptors, that are normally upregulated when EC is activated, were 
measured. A) MCP-1 gene expression between AGE and BSA treatment was not significant; 
N=4, P=NS B) RAGE mRNA was also not significantly affected by AGE treatment in HCAEC 
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Fig 17. AGE may not be signaling through the RAGE receptor in RAW 264.7 murine 
macrophages. A) RAGE, the receptor for AGE is downregulated in AGE stimulated RAW cells 
compared with BSA and untreated control treated wells N=4, P<0.05. B) TNFα mRNA is not 







































































Fig 18. AGE indirect effect on EC does not affect gene translation. A) RAGE mRNA B) MCP-1 
mRNA gene expression is not significantly different between EOMA cells incubated with RAW-
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Fig 16 C) AGE stimulation of EC does not affect gene translation. C) TNFα and D) PLGF mRNA 
are not significantly different in AGE treated RAW media incubated EOMA cells when 







































































There is extensive documentation in the literature from in vitro cell culture 
experiments, animal studies, and human studies that establishes that arteriogenesis is 
reduced by diabetes. However, the mechanism by which this reduction occurs is not well 
defined.  
Our lab has been investigating the hypothesis that diabetes may inhibit arteriogenesis by 
interfering with the regulation of PLGF expression. In previous studies, our group showed that 
mice fed a Western diet for 6 months had a reduced level of PLGF expression in skeletal muscle. 
This effect was seen both as a reduction of baseline PLGF levels, and as an impaired ability to 
upregulate PLGF after the physiological stimulus of femoral artery ligation [1]. Further in vitro 
studies were carried out in an attempt to identify the metabolic factor(s) causing this reduction. 
However, treatment of mouse and human skeletal muscle cells with cholesterol, oxidative stress, 
glucose, and insulin failed to produce significant and consistent effects on PLGF expression. 
Since the mice had been exposed to long-term hyperglycemia, a possible role for advanced 
glycation end products (AGE) was next considered. AGE was quantified in mouse quadriceps 
femoris and gastrocnemius-plantaris-soleus muscles and was found to be significantly 
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increased [117], suggesting that formation of AGE could be a major contributing factor to 
the decrease in PLGF caused by the Western diet in our study. 
In the present study, we set out to build on these findings by 1) determining 
whether AGE could reduce PLGF expression in EC and SKMC and 2) if so, identifying 
the signaling mechanism by which AGE exerts this effect. We initially hypothesized that 
AGE would act directly on EC and SKMC to reduce PLGF by acting through its receptor, 
RAGE to generate TNFα. Therefore, we first tested the direct effect of AGE treatment on 
PLGF expression in EC and SKMC. 
Effect of AGE Treatment on PLGF Expression in EC and SKMC 
 
Contrary to our expectations, direct treatment of HCAEC, HSKMC and MSKMC 
with 1000μg/ml and 1500μg/ml of AGE or BSA control for 24 h had no significant effect 
on PLGF mRNA or protein expression in HCAEC and HSKMC. However, there was a 
significant direct effect of AGE to reduce PLGF expression in MSKMC, compared to 
BSA.  These findings are consistent with a previous report that AGE treatment does not 
affect TNFα secretion in quiescent endothelial cells [284]  
Effect of AGE Treatment on TNFα Expression in EC and SKMC 
  
In addition to assessing the effect of AGE/BSA on PLGF expression in EC and 
SKMC, we also tested whether AGE or BSA could induce production of TNFα by these 
cell types. Interestingly, even after treatment of HCAEC and HSKMC with 1000 μg/ml 
of BSA or AGE for 24 h, TNFα was undetectable across all treatments and cell types 
(data not shown). Along with our results showing a lack of effect of AGE on PLGF 
expression in EC and SKMC, these data suggest that there is a general lack of 
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responsiveness of these cell types (at least when quiescent) to AGE treatment. At least 
one study has reported that AGE can induce secretion of TNFα in EC [284]. However, in 
agreement with our findings, another study found that HCAEC which were treated with 
the RAGE ligand S100A12 were unresponsive to direct treatment, despite the presence of 
the RAGE receptor [285]. These differences could be due to different EC types/lines 
being studied and/or may reflect differential responses in quiescent vs. activated EC. 
Based on our results showing a lack of direct effect of AGE on PLGF and TNFα 
in EC and HSKMC, we revised our research question to ask whether AGE could be 
having an indirect effect on PLGF in the in vivo Western diet studies. Previous studies by 
our lab have shown that PLGF is highly expressed by EC, and to a lesser extent by 
SKMC, and that the Western diet reduced PLGF in skeletal muscle (which is primarily 
composed of SKMC and EC) [117]. Therefore, we focused on measuring PLGF in these 
cell types. However, many other cell types interact with EC and SKMC in vivo. 
Therefore, we considered the possibility that AGE could be having an indirect effect on 
PLGF expression in EC and/or SKMC in vivo, by activating signaling pathways in other 
cell types which then in turn release mediators that signal to EC and SKMC. Other 
previous results from our lab showing that recombinant TNFα and IL-1 reduced PLGF 
expression in HCAEC were consistent with this possibility (unpublished). Therefore, we 
developed a revised hypothesis: AGE induces TNFα production by macrophages, and 




Effect of AGE Treatment on TNFα and PLGF Expression in RAW 264.7 Cells 
 
AGE is said to act as an antigenic substance that is recognized by macrophages 
and induces inflammatory cytokine production [286], similarly to the response of 
differentiated monocytes/macrophages in inducing inflammatory signaling to resolve an 
injury or clear foreign material from the body [254]. To test our revised hypothesis that 
macrophages (not EC or SKMC) respond directly to AGE by releasing TNFα, RAW 
264.7 murine macrophages were treated with BSA or AGE at 1000 μg/ml or 1500 μg/ml 
for 24 h. AGE treatment stimulated TNFα overexpression, compared to BSA-treated or 
untreated cells (Fig 10). Thus, we conclude that RAW 264.7 macrophages are activated 
by AGE, causing them to secrete inflammatory cytokines.  
Our results are consistent with reports from other cell types. There is an 
established relationship between inflammation and AGE, where glycated albumin is 
associated with stimulating monocytic cells to produce high amounts of pro-
inflammatory cytokines. For example, AGE has been shown to induce inflammation that 
leads to diabetic retinopathy by inducing retinal microglial cells to over secrete TNFα. 
These authors also showed that production of TNFα by microglial cells in a glycated 
albumin environment increases with time of exposure [287]. In our study, we also 
measured TNFα secretion by RAW 264.7 macrophages treated with AGE for 24 h and 48 
h and found that TNFα increases as time increases (data not shown). In our study, we also 
saw that the effect of AGE was concentration dependent, with 1500 μg/ml AGE causing 
more TNFα production than 1000 μg/ml AGE. Similarly, others have shown that more 
AGE formation results in a greater effect on macrophage stimulation and more TNFα 
production [275]. The relationship between AGE and TNFα is also well established in 
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human patients. In a study using a multivariable stepwise linear regression analysis, AGE 
levels were correlated with TNFα and glucose levels in the blood of Type 2 diabetic 
patients. Therefore, TNFα and AGE have now been proposed as clinical measurements to 
predict the presence and severity of vascular complications in patients with type 2 
diabetes [288]. 
In addition to inflammatory cytokines, macrophages have been reported to 
produce numerous growth factors [65]. Therefore, we tested the protein level of PLGF in 
the RAW 264.7 cells. PLGF protein was undetectable in all treatment groups, suggesting 
that macrophages do not make significant amounts of PLGF compared to EC and SKMC 
[289]. This finding, along with our results from EC above, demonstrates that our 
proposed AGE-TNFα-PLGF signaling pathway cannot occur entirely within either EC, 
SKMC, or macrophages, but must involve intercellular communication. 
Effect of Recombinant TNFα and IL-1 Treatment on PLGF Expression in EC and 
SKMC 
 
To determine whether PLGF expression in EC and SKMC is responsive to 
inflammatory cytokines, HCAEC, HSKMC and MSKMC were treated with recombinant 
TNFα and IL-1.  In HCAEC, TNFα significantly reduced PLGF across all concentrations 
tested (0-50 ng/ml, Fig 7). Interestingly, given the marked effect of TNFα on HCAEC, 
there was no effect of TNFα on PLGF expression in HSKMC and MSKMC (Fig 8). 
Treatment of HCAEC with IL-1 had no effect on PLGF expression (Fig 9). These results 
suggest that EC may be more important than SKMC as a cell type in which PLGF 
expression is modulated by inflammatory mediators. A possible further conclusion is that 
altered expression of PLGF in EC, not SKMC, may have primarily been responsible for 
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the reduced PLGF levels we observed in skeletal muscles of Western diet fed mice. 
These findings also suggest that TNFα, but not IL-1, is a potential mediator of this effect. 
Additional studies are necessary to determine whether these conclusions are correct. 
TNFα has a multifaceted role in arteriogenesis. Growth factors like PLGF and 
MCP-1 are produced by EC in response to shear stress and act as chemoattractant to 
direct the migration of macrophages to the site of remodeling, where they produce TNFα. 
TNFα stimulates smooth muscle cell proliferation and migration to enlarge the vessel, but 
can also lead to alteration in shear stress perception [290] and monocyte function [291]. 
Furthermore, overproduction of cytokines leads to poor vessel growth, e.g. associated 
with diabetes [292]. Therefore, although a certain level of TNFα is needed in the process 
of arteriogenesis, overstimulation of TNFα production leads to reduced blood vessel 
growth [293]. 
 
Effect of RAW 264.7 Conditioned Media on PLGF Expression in EOMA cells 
 
We next treated EOMA mouse endothelial cells with media aspirated from AGE-
treated RAW cells. After 24 h of incubation with EOMA cells, media from AGE-treated 
RAW cells still contained a significantly higher level of TNFα than media from BSA or 
untreated-control RAW cells (Fig 11). In the present study, it is not possible to determine 
whether all of the TNFα measured at the conclusion of the incubation with EOMA cells 
was derived from the RAW 264.7 cells, or whether treatment of EOMA with the RAW 
264.7 media was able to induce some additional TNFα production by EOMA cells. RAW 
264.7 media was centrifuged before use to remove any cells; therefore, any TNFα present 
104 
 
at the conclusion of the experiment was either present in the media when it was first 
added to EOMA, or was produced by EOMA. To gain some potential insight into 
whether EOMA cells were producing TNFα themselves, we assessed the level of TNFα 
mRNA in EOMA cells following treatment with RAW 264.7 media. TNFα mRNA was 
not significantly increased in the AGE-treated RAW media incubated EOMA cells 
compared to BSA or untreated control RAW-treated media EOMA cells (Fig 12). This 
observation suggests that most, if not all, of the TNFα present in the media at the 
conclusion of the incubation with EOMA cells was derived from RAW 264.7 cells, in 
support of our intercellular signaling hypothesis. 
This was similar to the results obtained from a study where HCAEC were 
incubated with monocyte conditioned medium, obtained from LPS or S100A12-
stimulated primary human monocytes. There was high expression of inflammatory 
cytokines, for example, TNFα, IL-8 and IL-6, illustrating that monocytes as well as 
monocyte-derived cytokines could interact with vascular endothelial cells  [285].   
We then assessed PLGF levels in the EOMA cells treated with RAW 264.7 
conditioned media, and obtained the very striking result that PLGF protein levels were 
significantly reduced in EOMA cells exposed to both the AGE-treated and BSA-treated 
RAW media for 24 h  (Fig 13A-B). This was a fairly rapid response, as we also found 
that stimulation of RAW cells for as little as 4 h was sufficient to produce a reduction in 
PLGF when the media was transferred to EOMA cells for 18 h (Fig 13C).  As discussed 
above, AGE-stimulated RAW media contained high levels of TNFα, which we would 
expect to be the most likely cause of the reduced PLGF (consistent with our results from 
treatment of HCAEC with recombinant TNFα discussed above). However, the 
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unexpected observation that media from BSA-treated RAW 264.7 cells also had an effect 
to reduce PLGF levels is not consistent with our hypothesis, since TNFα was not 
significantly increased in media from BSA-treated RAW 264.7 cells. Since direct 
treatment of EC with BSA did not affect PLGF in our earlier experiments, we conclude 
that BSA treatment of RAW 264.7 cells induced some type of response resulting in the 
secretion of additional mediator(s) that affected PLGF in the EOMA cells. It is possible 
that our BSA solution induced an inflammatory response in the RAW 264.7 cells, since 
the BSA is bovine-derived whereas RAW 264.7 cells are murine in origin. There appears 
to be a complex and incompletely understood relationship between macrophages and 
albumin. For instance, although the liver is known to be the major source of albumin 
production in the body, there are recent reports of non-hepatic production of albumin, 
including by activated macrophages [294, 295]. Interestingly, another study has shown 
that albumin can elicit an inflammatory response under certain circumstances [296].  
 
 
Effect of Endothelial Cell Activation on Responsiveness to AGE 
 
A study comparing the response of quiescent endothelial cells and activated 
endothelial cells to AGE found that whereas quiescent endothelial cells were 
unresponsive, activated endothelial cells responded to AGE by production of TNFα 
[284]. Therefore, we wondered whether the lack of response of HCAEC to AGE in the 
present study could be due to the relatively quiescent state of the cells. To test this 
possibility, HCAEC were incubated with BSA or AGE at 1000μg/ml and grown to 80% 
confluence, then activated with a combination of inflammatory mediators (IL-1, LPS and 
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IFN-γ) for 24 h. Interestingly, in the activated HCAEC, AGE treatment resulted in an 
increase in TNFα production in HCAEC, compared to the BSA and untreated control 
cells (Fig 11A). This finding is consistent with the above-mentioned study and 
underscores that AGE may have a greater effect on TNFα production in an inflammatory 
environment such as that found in type II diabetes. In a separate experiment, HCAEC 
were also stimulated directly with LPS, a known inducer of TNFα [63]. LPS is found in 
the outer wall of gram-negative bacteria and induces production of TNF in macrophages. 
PLGF was significantly decreased in response to the higher concentration of LPS 
(500ng/ml; Fig 14B), consistent with an effect of TNFα to reduce PLGF. 
Mouse Multiplex Cytokine Assay 
 
Since we obtained the unexpected finding that PLGF was reduced in EOMA cells 
by BSA-treated RAW media even though TNFα was not induced, we sought to determine 
what other cytokines were contained in the BSA-treated RAW media that could be 
having an effect on PLGF. To gain insight into this question, we carried out a multiplex 
6-panel mouse cytokine assay to measure IFN-γ, IL-1, IL-6, IL-10, IL-17 and TNFα in 
both BSA- and AGE-treated RAW cell media. Our results showed that TNFα and IFN-γ 
were the most abundantly secreted cytokines in the RAW media after both treatments 
(Fig 12A). The results also confirmed that media from AGE-treated RAW cells had a 
higher level of TNFα than media from BSA and untreated control RAW cells, consistent 
with our earlier results using ELISA. Interestingly, IL-10 and IFN-γ also showed a trend 
towards increased expression in AGE-treated RAW cell media, with p=0.06 (Fig 15B-C). 
It is possible that this trend could become significant with an increased sample size. 
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However, our multiplex assay did not identify an obvious potential mediator for the effect 
of BSA-treated RAW cell media on PLGF expression in EOMA cells. 
Arteriogenesis is a complex process which involves first an upregulation of 
inflammatory mediators and then a downregulation. This could explain the presence of 
IL-10, which is an anti-inflammatory cytokine produced by macrophages in order to end 
an on-going inflammatory process. In an interesting experiment in a mouse model of 
hindlimb ischemia, TNF-α, IFN-γ and IL-10 were initially increased in the presence of 
ischemia. However, after human macrophages were transplanted systemically, TNF-α, 
IFN-γ, IL-4, IL-5, IL-6, and IL-10 were reduced but collateral growth was strongly 
increased [256]. Similarly, we observed TNF-α, IFN-γ and IL-10 to be increased (or 
tending towards increase) in our study.  
Macrophages are known to exist as M1 (proinflammatory) and M2 (anti-
inflammatory) subtypes. Interestingly, both subtypes were found to be present in 
ischemic limbs of wild type and a high fat diet fed mice model. IFN-γ and TNFα are 
markers for the M1 proinflammatory subtype, whereas arginase-1 and IL-10 are markers 
for the M2 anti-inflammatory subtype. Markers for both subtypes were increased in the 
ischemic hindlimb. It is thought that this reflects the body’s attempt to balance out the 
rise in proinflammatory stimulation by increasing the differentiation of macrophages into 
the anti-inflammatory M2 subtype, which has been reported to promote arteriogenesis 
[297] and is necessary in ischemia-induced vessel growth in type 2 diabetic mice [298]. 
Although we did not examine macrophage subtypes in our in vitro studies, the markers 
we observed to be present are consistent with the above-described in vivo studies. 
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Gene Expression for Markers of Endothelial Cell and Macrophage Activation 
 
Gene expression of adhesion molecules (ICAM-1, VCAM-1), growth factors 
(MCP-1), cytokines (TNF-α) and receptors (RAGE) that are known to be upregulated in 
activated EC/macrophages was quantified by real-time PCR in order to determine 
whether direct and/or indirect treatment of cells with AGE or BSA induced activation. 
When HCAEC were treated directly with AGE or BSA, there was no significant effect on 
the expression of these genes (Fig 13A-E), showing that AGE itself does not activate 
quiescent EC. Interestingly, the RAGE receptor did show a non-significant trend (p=0.08) 
towards increase with AGE treatment. This result does confirm that RAGE is expressed 
in quiescent EC. However, since there was no direct effect of AGE on quiescent EC, the 
receptor is either not present on the cell surface or its signaling is otherwise inactive in 
quiescent EC.  
When RAW 264.7 cells were treated with AGE, we obtained the surprising 
finding that RAGE mRNA was downregulated (FIG 17A) while TNFα mRNA was not 
significantly affected (Fig 17B). Our previous results demonstrates that AGE causes 
RAW cells to produce TNFα. The gene expression results suggest that 1) the increase in 
TNFα protein may be post-transcriptional and 2) this effect is not mediated through 
RAGE signaling. In fact, other groups have shown that AGE signals through TLR4 on 
monocytes. Interestingly, in those studies, both HCAEC and monocytes were found to 
express TLR4 and RAGE; however, HCAEC were not responsive to direct stimulation 
with AGE, (as shown by undetectable TNFα expression) despite having both receptors. 
TLR4 also has a co-receptor (CD14) and these authors showed that CD14 is expressed on 
the monocyte/macrophage cell surface but not by EC. They further identified CD14 as 
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necessary in order for AGE to produce a direct effect [285]. Although we did not analyze 
CD14 in the present study, our results are consistent with a non-RAGE mediated effect of 
AGE to induce TNFα production in macrophages, but not EC. 
 We also assessed mRNA for activation markers in EOMA exposed to BSA- and 
AGE-treated RAW cell media. Again, there was no significant effect of the AGE-treated 
RAW media compared to the BSA-treated RAW media (Fig 18A-D). It is interesting to 
note that MCP-1 was not upregulated by the treatment. It is possible that MCP-1 was not 
upregulated because PLGF, which acts to promote the function of MCP-1, is 
downregulated by the AGE-treated RAW media [171].  
Possible Mechanism 
 
Diabetes has been established to impair arteriogenesis through inhibition of 
growth factor production and release, and advanced glycation end products (AGE) have 
been implicated in this effect. However, the mechanism through which this occurs has 
not been established. In this study, we provide new insights by showing that PLGF, a key 
arteriogenic growth factor produced by endothelial cells which is important in the early 
phase of arteriogenesis, was reduced by AGE via a mechanism involving induction of 
macrophage inflammatory cytokine secretion.  
Decreased macrophage infiltration to sites of arteriogenesis is known to occur in 
type II diabetes [182]. Under normal conditions, PLGF binds to VEGFR-1 on 
macrophages [299] and has a chemotactic effect to attract macrophage infiltration. 
Macrophages then release additional arteriogenic cytokines like TNFα and MCP-1 that 
allow further macrophage migration into the tissues, smooth muscle cell proliferation and 
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collateral growth. We speculate that in the setting of type II diabetes, monocytes are 
activated by AGE and overexpress TNFα, which counters the production of PLGF 
through a negative feedback mechanism, thereby limiting the monocyte infiltration and 




In order to confirm that TNFα is the mediator of the effect of AGE-treated RAW 
cell media on PLGF expression in EC, studies with TNFα and TNFR inhibitors are 
necessary. The effect of BSA-treated RAW cell media on PLGF was unexpected and not 
consistent with the hypothesis that TNFα is the only macrophage-derived cytokine 
influencing PLGF expression. Therefore, further studies are necessary to identify how 
other cytokines such as IL-10 and IFN-γ can contribute to activation of HCAEC and 




mediating the effects of AGE on both the macrophage and the endothelial cells are also 
necessary.   
Limitations of the Study 
 
The BSA and AGE products used in this study were synthesized in the laboratory. 
We found that BSA itself had an effect on macrophage cytokine secretion, confounding 
our results and possibly reflecting an immune response of the murine cells to the bovine 
protein. Therefore, future studies should avoid this effect by either 1) using commercially 
synthesized AGE compounds which do not promote such a reaction, 2) matching the 
species of the albumin to the cell type, and/or 3)  de-glycosylating albumin by treatment 
with PNGase before use, which some researchers believe decreases its antigenicity.  
Another limitation of the study is that only healthy (non-diabetic) cell lines were 
used in this study. Therefore, our experiments may not accurately model how cells would 
respond to AGE in the diabetic environment. Studies of aged cells/animals would also 
increase the clinical relevance of the research, since peripheral vascular disease and 
coronary artery disease primarily affect the elderly. 
Clinical Implications 
 
Our results, along with those from other groups, suggest that targeting the innate 
immune response might be one effective way to clinically improve arteriogenesis. 
Transplantation of healthy monocytes into an area of collateral growth is currently being 
explored. Another strategy could be to block the effects of AGE on monocytes, e.g. by 
application of an inhibitor that targets steps in the pathway to suppress the production of 
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cytokines. Anti-inflammatory drugs are another possibility. AGE breakers that degrade 
AGE before it could exert negative effects could also potentially promote and restore 








These studies demonstrate that AGE can reduce PLGF expression in endothelial 
cells by inducing the secretion of inflammatory mediators such as TNFα by macrophages. 
Therefore, AGE/TNFα signaling via macrophages may be a possible mechanism for 
reduced PLGF expression and reduced collateral growth in people with type 2 diabetes. 
These findings provide novel insights into diabetic vascular disease and may lead to 
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